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Abstract
Sepsis is characterized by a severe systemic inflammatory response to infection that is
associated with high morbidity and mortality despite optimal care. Invariant natural killer T
(iNKT) cells are potent regulatory lymphocytes that can produce pro- and/or anti-inflammatory
cytokines, thus shaping the course and nature of immune responses; however, little is known
about their role in sepsis. We demonstrate here that patients with sepsis/severe sepsis have
significantly elevated proportions of circulating iNKT cells in their peripheral blood, as
compared to non-septic patients. We therefore investigated iNKT cells in mice with intraabdominal sepsis (IAS). Our data show that iNKT cells are pathogenic in IAS, and that T helper
(Th)2-type polarization of iNKT cells using the synthetic glycolipid OCH significantly reduced
mortality from IAS. This reduction in mortality is associated with the systemic elevation of the
anti-inflammatory cytokine interleukin (IL)-13, and reduction of several pro-inflammatory
cytokines within the spleen, notably IL-17. Finally, we show that administration of OCH in
septic mice is associated with significantly reduced apoptosis of splenic T and B lymphocytes, as
well as macrophages, but not natural killer cells. We propose that modulation of iNKT cell
responses towards a Th2 phenotype may be an effective therapeutic strategy in sepsis.
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Chapter 1: Introduction
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1.1 Introduction to Sepsis
1.1.1 Epidemiology of Sepsis
Sepsis is defined as an overwhelming systemic inflammatory response to an infection [1].
It is one of the leading causes of death among patients in non-coronary intensive care units [2, 3],
and the tenth leading cause of death overall in North America [4]. With a mortality rate of 20%
to 50% in the acute setting [5], sepsis also substantially reduces the quality of life among
survivors [6, 7]. The management of sepsis also presents a huge financial burden for the
healthcare system: the care of septic patients costs as much as $50,000 per patient [8], resulting
in an economic burden of nearly $17 billion annually in Canada and the United States [2]. It is
more worrisome that a 75% increase in the number of patients diagnosed with severe sepsis has
been observed over the past two decades. This may be explained partly by the improved care of
the increasing number of individuals surviving into their 70s, 80s, and 90s and by the associated
co-morbidities of the elderly, including cancer and diabetes [9]. Therefore, as the general
population continues to age, the incidence of sepsis is projected to increase significantly in the
forthcoming years, leading, for example, to over 1 million cases of severe sepsis in 2020 in the
United States alone [2].
1.1.2 Diagnosis of Sepsis
Definitions of sepsis, severe sepsis, and septic shock were previously based on expert
advice, using criteria that identified progression of the infection along with appropriate
physiological responses [10]. In particular, the presence of the systemic inflammatory response
syndrome (SIRS; Table 1) was suggested to be a precursor of severe sepsis [11].
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Table 1: Clinical criteria for severe inflammatory response syndrome (SIRS).
SIRS Criteria
At least two or more of the following:
1.

Temperature >38°C or < 36°C

2.

Heart Rate > 90/min

3.

Respiratory Rate > 20/min or PaCO2 < 32 mmHg

4.

White Blood Cell Count >12 × 109 / L or < 4 × 109 / L

3

However, studies illustrating the limited value of SIRS criteria in predicting the risk of
developing organ dysfunction, shock, and death [12-14], prompted the development of new
scoring systems and clinical criteria. Consequently, the 2001 International Sepsis Definitions
Conference (ISDC), sponsored by the Society for Critical Care Medicine (SCCM), the European
Society of Intensive Care Medicine (ESICM), the American College of Chest Physicians
(ACCP), the American Thoracic Society (ATS), and the Surgical Infection Society (SIS),
expanded the list of signs and symptoms of sepsis (Tables 2 and 3) to reflect clinical bedside
experience [15]. These definitions of sepsis, severe sepsis, and septic shock were also based on
consensus guidelines and expert opinion, and exhibit broad physician endorsement. Additionally,
evidence-based recommendations from the Surviving Sepsis Campaign (SSC) Management
Guidelines Committee [16] provided treatment algorithms to appropriately resuscitate and
manage patients with sepsis.
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Table 2: Diagnostic criteria for sepsis.

Infection, documented or suspected, and two or more of the following:
General variables
Fever (>38.3°C)
Hypothermia (core temperature <36°C)
Heart rate >90 min-1 or >2 SD above the normal value for age
Tachypnea
Altered mental status
Significant edema or positive fluid balance (>20 mL/kg over 24 hrs)
Hyperglycemia (plasma glucose >140 mg/dL or 7.7 mmol/L) in the absence of
diabetes
Inflammatory variables
Leukocytosis (WBC count >12,000 µL-1)
Leukopenia (WBC count <4000 µL-1)
Normal WBC count with >10% immature forms
Plasma C-reactive protein >2 SD above the normal value
Plasma procalcitonin >2 SD above the normal value
Hemodynamic variables
Arterial hypotension (SBP <90 mm Hg; MAP <70 mm Hg; or an SBP decrease >40
mm Hg in adults or >2 SD below normal for age)
Organ dysfunction variables
Arterial hypoxemia (PaO2/FIO2 <300)
Acute oliguria (urine output <0.5 mL/Kg hr or 45 mmol/L for at least 2 hrs, despite
adequate fluid resuscitation)
Creatinine increase >0.5 mg/dL or 44.2 µmol/L
Coagulation abnormalities (INR >1.5 or a PTT >60 secs)
Ileus (absent bowel sounds)
Thrombocytopenia (platelet count, <100,000/µL)
Hyperbilirubinemia (plasma total bilirubin >4 mg/dL or 70 µmol/L)
Tissue perfusion variables
Hyperlactatemia (> upper limit of lab normal)
Decreased capillary refill or mottling
Abbreviations: WBC: white blood cell; SBP: systolic blood pressure; MAP: mean arterial
pressure; INR: international normalized ratio; aPTT: activated partial thromboplastin time.
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Table 3: Diagnostic criteria for severe sepsis.

Severe sepsis - sepsis-induced tissue hypoperfusion or organ dysfunction (any of the
following thought to be due to the infection):
Sepsis-induced hypotension
Lactate greater than the upper limits of normal laboratory results
Urine output <0.5 mL/kg.hr for >2 hrs, despite adequate fluid resuscitation
ALI with PaO2/FIO2 <250 in the absence of pneumonia as infection source
ALI with PaO2/FIO2 <200 in the presence of pneumonia as infection source
Creatinine >2.0 mg/dL (176.8 µmol/L)
Bilirubin >2 mg/dL (34.2 µmol/L)
Platelet count <100,000
Coagulopathy (INR > 1.5)
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1.2 Management of Sepsis
The management and treatment of sepsis has evolved dramatically over the last forty
years [17, 18]. While there is an abundance of treatment algorithms for managing patients with
sepsis, I will briefly highlight the most critical therapeutic strategies, as recommended by the
Surviving Sepsis Campaign [16, 19, 20].
1.2.1 Early Goal-Directed Therapy
The landmark study by Rivers et al [21] emphasized the concept of early goal-directed
therapy (EGDT) in the treatment of sepsis: measures to improve physiological parameters, such
as blood pressure and tissue oxygen delivery, immediately upon diagnosis of sepsis significantly
reduced patient mortality, disease severity scores, and severity and duration of organ dysfunction
[22]. These measures included the use of fluids, vasopressors, and packed red cells, and early
initiation of mechanical ventilation to attain physiologically-normal hemodynamic parameters as
rapidly as possible. The overwhelmingly positive results reported by Rivers et al prompted
hospitals to deploy “sepsis teams” and “critical care outreach teams” to manage patients with
severe infections in the wards [20, 23-26], resulting in improved clinical outcomes [27].
1.2.2 Antibiotic Therapy
Early parenteral broad-spectrum antimicrobial therapy significantly improves clinical
outcomes in sepsis [28]. Antibiotic administration within four hours of diagnosing elderly
patients (age over 65) with community-acquired pneumonia significantly reduced in-hospital
mortality, 30-day mortality, and length of stay in hospital [28]. Every additional hour without
antibiotics increased the risk for death in hypotensive septic patients by 7.6% during the first 6
hours [29]. However, treatment effectively targeting the responsible pathogen is critical [30],
since the ineffectiveness of antimicrobial treatment against a micro-organism identified in blood
7

cultures is strongly associated with death [31]. Compliance with the SSC guidelines, however,
remains low with respect to antibiotic administration: the mean delay to first infusion of
antibiotics remained in excess of 3 hours [23], and as many as 68% of patients did not receive
their first dose within this period [19].
1.2.3 Hemodynamic Resuscitation
Efficient restoration of circulating blood volume is the primary goal of resuscitation in
septic patients [32], although modalities of treatment continue to evolve. The use of crystalloids
rather than colloids is supported by current literature. While both result in similar ejection stroke
volume and oxygen delivery [33], patients receiving colloids had greater renal impairment [34].
The use of albumin in sepsis also remains controversial. Although it was the first product to be
broadly used for intravenous fluid loading, a meta-analysis comparing albumin with other fluid
loading agents identified an increased risk for death among patients who received albumin for
supportive treatment during shock [35]. In septic patients with hypoalbuminemia, however, the
use of albumin improved fluid loading [36], although its cost-effectiveness has been questioned
[37]. Since the publication of the EGDT results by Rivers et al [21], the transfusion of packed
red cells has also been regarded as a valuable approach to improving tissue oxygenation. Liberal
transfusion of blood, however, has been shown to be potentially ineffective [38, 39]. However, in
the setting of severe sepsis and septic shock the theoretical risks appear balanced by the benefits
in terms of tissue oxygenation [40].
1.2.4 Vasoactive Drugs
Vasopressors may allow therapies to be applied earlier and more aggressively in order to
improve physiological parameters [41], although their influence on mortality is unclear [42].
Norepinephrine and dobutamine improve hepatic and splanchnic circulation [43], while
8

dopamine and epinephrine are vasoconstrictors that also increase cardiac output. However, the
latter may cause harmful metabolic effects if used inappropriately [44]. Vasopressin (an
analogue of anti-diuretic hormone) is recommended as a second-line vasopressor, although it
may be used as a first-line agent in the treatment of septic shock in select cases [45, 46].
1.2.5 Adjunct Therapeutic Strategies
Low tidal volume mechanical ventilation and strict blood glucose control are crucial
components of the care provided to critically-ill patients. Low tidal volume (≤ 6 ml/kg) improves
survival in patients with acute respiratory distress syndrome [47, 48], compared to “standard”
mechanical ventilation (12 ml/kg). Landmark studies by van den Berghe et al [49] suggested that
aggressive insulin therapy improved 30-day survival in critically-ill patients, and dramatically
reduced their morbidity and length of hospital stay.
1.2.6 Prognosis in Sepsis
Earlier identification of patients with sepsis (through guidelines and training of healthcare
personnel) and improved treatment algorithms have significantly reduced the early mortality in
sepsis [17]. Most patients survive the early hyper-inflammatory phase of sepsis and enter a more
protracted phase [50, 51]: more than 70% of deaths in sepsis occur after the first 3 days of the
disorder, with many deaths occurring weeks later. If the patient dies in the first few days, death
will probably have been caused by cytokine-driven hyper-inflammation and multiple organ
failure, especially cardiovascular collapse (Figure 1). In many situations of protracted sepsis,
however, death is due to the family's decision to change from aggressive support measures to
comfort measures because of the patient's many, severe pre-existing comorbidities and small
probability of meaningful recovery.
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Figure 1: Inflammatory responses among septic patients.
This figure was adapted from Hotchkiss et al [17]. (A) The initial response in otherwise-healthy
patients with severe sepsis is characterized by an overwhelming hyper-inflammatory phase with
fever, hyperdynamic circulation, and shock. Deaths during this phase are generally due to
cardiovascular collapse, metabolic and physiologic disruption, and multi-organ failure. (B) In
elderly patients with numerous comorbidities that impair immune response, sepsis results in a
blunted or absent hyper-inflammatory phase. Patients rapidly develop impaired immunity and an
anti-inflammatory state, and may die from secondary infections. (C) Some patients with sepsis
alternate between hyper- and hypo-inflammatory states, especially if they develop superimposing
infections. They eventually become severely immunosuppressed and may die from secondary
infections or organ failure.
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In a post-mortem study, Torgersen et al determined that 80% of surgical patients
admitted to an intensive care unit had unresolved septic foci; only 52 of 97 autopsy-confirmed
pneumonias were appropriately diagnosed during their intensive-care admission. Additionally,
peritonitis accounted for many unresolved septic foci. While such ongoing infections are not
necessarily the main cause of death, the real cause of death and organ failure in most patients
dying of sepsis is still unclear.

1.3 Immunology of Sepsis
1.3.1 Immunological Mechanisms in Sepsis
In sepsis, systemic exposure to pathogenic microbial lipids initiates a complex and
dysregulated immune response [18, 52, 53]. Macrophages and antigen-presenting cells (APCs)
recognize and phagocytose invading bacteria. These cells subsequently produce proinflammatory cytokines, including interleukin (IL)-1β, tumour necrosis factor (TNF), and IL-6,
as well as chemokines such as IL-8 [18]. Following the recruitment of neutrophils and
lymphocytes, and the resulting surge of more pro-inflammatory cytokines such as interferon
(IFN)-γ [54-57], some patients develop an overwhelming hyper-inflammatory response with
systemic physiological effects [18]. The intensity of this initial hyper-inflammatory phase is
determined by factors such as pathogen virulence, bacterial load, host genetic factors, age, and
patient comorbidities. In 30% of cases, mortality occurs within the first 72 hours because of the
cytokine-storm-mediated inflammatory response that leads to septic shock and multiple organ
failure.
Opposing anti-inflammatory processes are also concomitantly initiated to mitigate the
pro-inflammatory state. Studies of circulating cytokines in 464 patients with community-
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acquired infections demonstrated that, in addition to pro-inflammatory cytokines, concentrations
of the potent anti-inflammatory cytokine interleukin 10 (IL-10) were significantly increased [58]:
additionally, a high ratio of IL-10 to TNF-α correlated with mortality in these patients. Other
studies have also documented a global cytokine depression in sepsis, with reduced production of
pro- and anti-inflammatory cytokines [59-61]. When whole blood from patients with and without
sepsis was stimulated with endotoxin, the production of TNF-α, IL-1β, and IL-6 from septic
patients was less than 10–20% of that found in non-septic patients [59]. Lipopolysaccharidestimulated monocytes from septic patients had profoundly decreased production of TNF-α, IL1β, and IL-6, compared to controls [60]. Similarly, when Sinistro et al stimulated blood
monocytes from septic and non-septic patients, fewer than 5% of monocytes from the septic
group produced cytokines, compared with roughly 15-20% of monocytes from non-septic
patients [62]. In a study by Weighardt et al, postoperative sepsis was associated with defects in
production of both proinflammatory and anti-inflammatory cytokines when monocytes were
stimulated by lipopolysaccharide [63]. These results indicate that patients with sepsis either
rapidly produce both pro- and anti-inflammatory cytokines, or produce a predominance of antiinflammatory cytokines, or produce reduced levels of cytokines overall.
1.3.2 Immunosuppression in Sepsis
Immunosuppression also occurs in individual organs during sepsis. In a study by Boomer
et al [64], lipopolysaccharide-stimulated splenocytes from patients with sepsis had reduced
production of both proinflammatory and anti-inflammatory cytokines, less than 10% of that in
patients without sepsis. Both spleens and lungs showed upregulated expression of selected
inhibitory receptors including programmed cell death 1 (PD-1), expansion of suppressor cells (T
regulatory cells and myeloid derived suppressor cells), and concomitant downregulation of
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activation pathways [64]. These results confirm that sepsis decreases the response of cells of the
innate and adaptive immune systems, and that multiple mechanisms of immunosuppression
occur in different organs.
Critically-ill patients who have normal immunity before admission may become
profoundly immune-compromised during protracted sepsis as a result of immunosuppression:
weakly-virulent or opportunistic pathogens, such as Stenotrophomonas, Acinetobacter,
Enterococcus, Pseudomonas, and Candida, especially affect septic patients with severely
depressed host immunity [65, 66]. Additionally, the reactivation of cytomegalovirus (CMV) and
herpes simplex virus (HSV) occurred in approximately 33% and 21%, respectively, of criticallyill patients with sepsis who were immune-competent prior to their infection [67, 68]. Meakins et
al [69] noted that patients with sepsis and trauma had loss of delayed type hypersensitivity
response to common recall antigens such as measles and mumps, a finding that correlated with
mortality.
1.3.3 Apoptosis in Sepsis
Apoptosis of the innate and adaptive immune systems plays a critical role in the antiinflammatory and immunosuppressive host response during sepsis. Hotchkiss et al observed a
striking apoptosis-induced loss of cells of the innate and adaptive immune systems in the spleen,
including CD4+ and CD8+ T cells, B cells, and dendritic cells [70, 71]. During a life-threatening
infection when clonal expansion of lymphocytes should be occurring, the loss of immune cells is
particularly striking, and occurs in all ages, including pediatric and neonatal patients with sepsis
[72, 73]. In addition to the widespread apoptosis that occurs in the spleen during sepsis [70, 7476], Le Tulzo et al observed a marked increase in apoptosis among circulating lymphocytes
obtained from patients in septic shock compared to critically ill non-septic patients [77]. This
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phenomenon is believed to lead to a profound and persistent lymphopenia that is associated with
poor outcome.
Caspases are the key enzymes involved in apoptosis, and also play critical regulatory
roles in the inflammatory response [78, 79]. They may be divided into two functionally distinct
subfamilies: those involved in apoptosis (caspase-2, caspase-3, caspase-6, caspase-7, caspase-8,
caspase-9 and caspase-10) and those related to cytokine processing and regulation of
inflammation (caspase-1, caspase-4, caspase-5 and caspase-12) [80, 81]. The pro-inflammatory
caspases, such as caspase-1 and caspase-5, are activated after assembly of an intracellular
structure, designated the inflammasome, and mediate the cleavage and activation of several proinflammatory cytokines, including IL-1β and IL-18 [80].
Apoptosis may be induced through two different pathways: a death receptor-initiated
caspase-8-mediated pathway and a mitochondrion-initiated caspase-9-mediated pathway [82,
83]. Either caspase-8 or caspase-9 can activate caspase-3, which is a crucial apoptotic protease in
the apoptotic cell-death mechanism. Caspase-8 can be activated by several ligands of the
different death receptors, including TNF-α, a key cytokine that increases in patients with sepsis,
and CD95L (also known as FasL). The mitochondrial pathway can be activated by a diverse
range of stimuli, including reactive oxygen species, radiation and chemotherapeutic agents [84].
Apoptosis contributes to immunosuppression during sepsis through the deletion of critical
effector cells including T and B cells, and the induction of anergy (the inability of a lymphocyte
to mount a complete response against a specific antigen) and T helper 2 (Th2)-cell responses in
surviving immune cells. The apoptosis of T and B cells significantly impairs the adaptive
immune response, and, by disabling the cross-talk between the adaptive and innate immune
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systems, also impairs the latter [17, 64, 74]. The apoptosis-induced reduction in the number of
dendritic cells (DCs), the most potent APCs, further compromises the innate and adaptive
immune responses [85]. Apoptosis also induces anergy and T helper 2 (Th2)-cell responses in
surviving immune cells [86, 87]. Furthermore, the uptake of apoptotic cells by macrophages and
DCs stimulates the release of anti-inflammatory cytokines, including IL-10 and transforming
growth factor-β (TGF-β), and suppresses the release of pro-inflammatory cytokines [87]. This
potential link between the release of IL-10 by apoptotic cells and immune suppression in sepsis
is underscored by studies showing that the circulating concentration of IL-10 is predictive of a
fatal outcome in patients with sepsis [58, 88]. In addition, uptake of apoptotic cells by
macrophages and DCs does not induce the expression of co-stimulatory molecules: therefore, T
cells that come into contact with APCs that have ingested apoptotic cells might either become
anergic or undergo apoptosis themselves [87].
1.3.4 Immunotherapy of Sepsis
Given the increasing knowledge about the mechanisms and effectors in sepsis, more than
thirty clinical trials of immunotherapeutic agents were initiated. The results were disheartening:
none showed any benefit and even worse, some drugs demonstrated reduced survival rates [89,
90] and were prematurely terminated. The paucity of knowledge about the molecular
pathophysiology of sepsis, the inability of animal models to correctly mimic the
pathophysiological processes leading to sepsis in humans, and the inability to account for the
influence of risk factors such as age, nutrition, gender, and various other co-morbidities in
patients [90] were identified as the key reasons for the failure of these trials.
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Table 4: Immunotherapeutic agents that have failed in human sepsis trials.
Immunotherapeutic Target
Treatment with anti-endotoxins
Anti-endotoxin antibodies
LPS analogs
Treatment with antagonists to
specific mediators
TNF
Anti-TNF antibodies
TNF receptors
IL-1 or IL-1RA
Coagulants
Antithrombin
Activated protein C
Tissue factor pathway
inhibitor
PAF
PAF antagonists

PAF-acetylhydrolase
PLA2: PLA2 inhibitor

Immunostimulation therapy
Immunoglobulins
Granulocyte colonystimulating factor, IFN-γ
Immunonutrition
Nonspecific interventions
Corticosteroid therapy
High-output hemofiltration

Drug

Company

Result

Ref.

Nebacumab
Eritoran

Withdrawn
Eisai

Increased mortality
No effect on mortality

[91]
[92]

Afelimomab

Abbott

[93]

Lenercept
Anakinra

Genentech
Amgen

Marginal reduction in
mortality
No effect on mortality
No effect in mortality

Antithrombin
III
Drotrecogin
alpha, rAPC
Tifacogin

Grifols

No effect on mortality

[96]

Eli Lilly

Increased mortality

[97]

Novartis

No effect on mortality

[98]

Lexipafant

British
Biotechnolo
gy Ltd.

No effect on mortality

[99]

No effect on mortality
No survival benefit

[100]
[101]

rPAF-AH
Varespladib

Anthera
Pharmaceuti
cals

[94]
[95]

IVIG
Molgramosti
m

N/A
Zenotech

No effect on mortality
Reduced ventilatordependent days and ICU
stay

[102]
[103]

Steroids

N/A
(Generic)
N/A

No effect on mortality

[104]

No evidence for use

[105]

-
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Since most patients rapidly progress to an immunosuppressive state, the focus of
immunotherapeutic approaches has shifted to the development of methods to augment host
immunity. Granulocyte macrophage colony stimulating factor (GM-CSF), a cytokine that
activates and induces production of neutrophils and monocytes or macrophages, has shown
potential as a treatment agent in sepsis [106, 107]. Patients who were in the immunosuppressive
phase of sepsis (as determined by persistent decreases in monocyte HLA-DR expression, a
common abnormality in sepsis), were treated with GM-CSF and had restoration of HLA-DR
expression, fewer ventilator-dependent days, and shorter hospital and intensive care unit days
[106]. In a paediatric sepsis study, Hall et al [107] treated immunosuppressed patients with GMCSF, which reduced the incidence of new nosocomial infections.
Another immunotherapeutic agent is interleukin 7 (IL-7), a cytokine that has been termed
the “maestro of the immune system” because of its diverse effects on immunity [108-112]. IL-7
induces proliferation of naive and memory T cells, thereby supporting the replenishment of
lymphocytes, which are relentlessly depleted during sepsis [64, 70, 71, 113]. In clinical trials at
the National Cancer Institute (NCI), it caused a doubling of circulating CD4+ and CD8+ T cells,
and an increase in size of spleen and peripheral lymph nodes by roughly 50% [110]. Similarly,
IL-7 significantly increased the levels of circulating CD4+ and CD8+ T cells in HIV-infected
patients with persistently low CD4+ T cells despite effective viral suppression [114]. IL-7
therefore reverses profound lymphopenia, a major pathological abnormality in sepsis. IL-7 also
has other additional actions that are highly beneficial in sepsis [109, 111, 112]: it increases the
ability of T cells to become activated, potentially restoring functional capacity of hyporesponsive
or exhausted T cells which typify sepsis [115, 116]; increases expression of cell-adhesion
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molecules, which enhance trafficking of T cells to sites of infection [115] and increases T-cell
receptor diversity, leading to more potent immunity against pathogens [111, 114].
IL-7 has shown efficacy both clinically and in animal models of infection. A case report
of a patient with idiopathic low CD4 T cells with progressive multifocal leukoencephalopathy
(PML) showed that IL-7 caused rapid increases in lymphocytes, decreased circulating JC virus,
and led to disease resolution [117]. In mice that were chronically infected with lymphocytic
choriomeningitis, IL-7 treatment enhanced T-cell recruitment to the infected site and increased
T-cell numbers, thereby improving viral clearance [111]. Unsinger et al showed that IL-7
restored the delayed type hypersensitivity response, decreased sepsis-induced lymphocyte
apoptosis, reversed sepsis-induced depression of IFN-γ (a cytokine that is essential for
macrophage activation), and improved survival in murine polymicrobial sepsis [115]. IL-7 was
also found to be beneficial in a fungal sepsis model that reproduces the delayed secondary
infections typical of patients in intensive care units [118]. IL-7 was able to reverse sepsisinduced T-cell alterations in septic shock patients [116]. Ex-vivo treatment of patients' cells with
IL-7 corrected multiple sepsis-induced defects including CD4+ and CD8+ T cell proliferation,
IFN-γ production, STAT5 phosphorylation, and Bcl-2 induction to that of healthy controls. This
functional restoration indicates that the IL-7 pathway remains fully operative during sepsis [116].
IL-7 is in clinical trials in patients with cancer, HIV-1, and PML. It has been well
tolerated in more than 200 patients and, unlike IL-2, a closely-related cytokine, it rarely induces
fever, capillary leak syndrome, or other clinical abnormalities associated with excessive proinflammatory cytokines [110, 119]. Because of its diverse beneficial effects on immunity and
excellent safety record, investigators at the National Cancer Institute have consistently ranked
IL-7 as one of the top potential immunotherapeutic molecules [120]. Because of its many
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beneficial effects on immunity, reported efficacy in bacterial, fungal, and animal sepsis models,
and clinical track record, IL-7 is believed to have enormous promise in the treatment of sepsis.
Another exciting immunomodulatory therapy that holds much potential in sepsis involves
blockade of negative costimulatory molecules present on T cells. The negative costimulatory
molecule PD-1 is inducibly expressed on CD4+ and CD8+ T cells [121, 122]. Signalling through
PD-1 inhibits the ability of T cells to proliferate, produce cytokines, or perform cytotoxic
functions. Persistent antigenic exposure as occurs in chronic viral infections such as HIV-1 and
viral hepatitis leads to excessive PD-1 expression and exhausted T cells [123, 124]. Antibody
blockade of PD-1 or its ligand (PD-L1) can reverse T-cell dysfunction and induce pathogen
clearance [124]. Similarly, three independent groups showed that blockade of the PD-1 pathway
improves survival in clinically relevant animal models of bacterial and fungal sepsis [125, 126].
PD-1 over-expression on circulating T cells from patients with sepsis correlated with decreased
T-cell proliferative capacity, increased secondary nosocomial infections, and mortality
[127]. Thus, expression of PD-1 or PD-L1 on circulating immune cells could function as a
valuable biomarker for the selection of candidates for blockade therapy. Importantly, postmortem study of patients with sepsis showed that PD-L1 was highly expressed on tissue
parenchymal cells, including endothelial cells, thereby providing opportunity for pathway
activation [128].
Another immunostimulatory cytokine receiving renewed interest as a potential
therapeutic agent in sepsis is IFN-γ, a potent monocyte, macrophage, and NK cell activator,
which produced encouraging results in a small trial of patients with sepsis. Docke et al
[129] treated patients with sepsis whose monocytes had reduced HLA-DR expression and
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produced decreased amounts of TNF-α after lipopolysaccharide stimulation. IFN-γ treatment
reversed the sepsis-induced monocyte dysfunction and resulted in eight of nine patients
successfully resolving the septic insult. Nalos et al reported on use of IFN-γ in a patient with
persistent staphylococcal sepsis [130]. IFN-γ therapy resulted in increased monocyte expression
of HLA-DR, increased numbers of IL-17-producing CD4+ T cells, and clinical resolution of the
sepsis. IFN-γ is approved for treatment of fungal sepsis in patients with chronic granulomatous
disease. In a randomized controlled trial, Jarvis et al [131] treated HIV patients who had
cryptococcal meningitis with IFN-γ: patients treated with IFN-γ had more rapid clearing of
cerebrospinal fluid than control patients.
Other molecules in early stages of testing have also shown efficacy in clinically relevant
animal models of sepsis. IL-15 is a pluripotent cytokine closely related to interleukin 7 [132] that
also acts on CD4+ and CD8+ T cells to induce proliferation and prevent apoptosis. A potential
advantage of IL-15 compared with IL-7 is its potent immunostimulatory and proliferative effects
on natural killer (NK) cells and dendritic cells. These cells have important roles in fighting
infection and are also severely depleted in sepsis. Inoue et al [132] reported that IL-15 blocked
sepsis-induced apoptosis of CD8+ T cells, NK cells, and dendritic cells, and improved survival in
sepsis due to cecal ligation and puncture and in primary pseudomonas pneumonia. The B and T
lymphocyte attenuator (BTLA) is an immunoregulatory receptor expressed by various innate and
adaptive immune cells. Activation of BTLA induces a potent immunosuppressive effect on T
cells and other immune cells. Adler et al [133] reported that BTLA null mice showed reduced
parasitaemia and faster clearing of malaria in a murine model of infection. Results in the cecal
ligation and puncture model of murine sepsis show similar protective effects: BTLA-null mice
have increased survival and reduced organ injury compared with wild-type mice [133].
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Lastly, anti-apoptotic therapies have also shown promise in early pre-clinical studies of
sepsis [113, 134, 135]. Mice that overexpress B-cell lymphoma 2 (BCL-2; a protein known to
protect against apoptosis mediated through the mitochondrial pathway) in T or B cells are almost
completely protected from sepsis-induced lymphocyte apoptosis [113]. In rat cardiomyocytes
exposed to endotoxin, Carlson et al observed that TNF-α-induced caspase activation that
subsequently caused cardiac dysfunction [78]. Lancel et al also demonstrated that caspases also
caused contractile dysfunction in cardiac myocytes exposed to endotoxin [79]; however, the
broad-spectrum caspase inhibitor zVAD.fmk (N-benzlyoxycarbonyl-valylalanyl- aspartylfluoromethylketone) had a protective effect on endotoxin-exposed myocytes. zVAD.fmk also
provided significant neuroprotection by reducing hippocampal neuronal cell death in
pneumococcal meningitis [136], and improved survival in a mouse model of cecal ligation and
puncture [134, 137]. Despite these favourable results, the use of caspase inhibitors for treating
sepsis may not be feasible for multiple reasons. Firstly, it is necessary to have a persistent and
nearly complete caspase inhibition to prevent cell death, because even a small amount of
activated caspase-3 is sufficient to initiate genomic DNA breakdown and lead to apoptotic cell
death [138]. Secondly, caspases have many functions in addition to their roles as cell-death
proteases and regulators of inflammation, including being essential for lymphocyte activation,
proliferation and protective immunity; blocking caspases therefore may have unintended
negative consequences by blocking the patient’s ability to mount an effective immune response.
Despite the challenges of developing immune-based therapy for a disease as complex as sepsis,
novel immune-adjuvants and immunomodulatory treatments offer hope in the battle against this
disease.
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1.4 Natural Killer T Cells and Sepsis
1.4.1 Characterization of Natural Killer T Cells
In the last decade, there has been increasing interest in natural killer T cells, a unique
population of lymphocytes that plays a central role as effectors and regulators of the septic
response by interacting with both the innate and adaptive immune systems [139].
NKT cells were originally defined in mice as a CD4-CD8- population that co-expresses
the T cell receptor (TCR) and NK1.1, a natural killer (NK) cell surface marker in certain mouse
strains [140]. Subsequent studies, however, have shown that a subset of NK1.1- cells may also
exhibit characteristics of NKT cells [141]. These cells can be broadly categorized into type I or
invariant NKT (iNKT) cells and type II NKT cells [141]. Unlike conventional T cells which
recognize peptide antigens presented in the context of the major Histocompatibility Complex
(MHC) class I or II molecules, NKT cells recognize glycolipid antigens presented on the MHC
class I-like molecule CD1d [141, 142]. CD1d is a member of a family of CD1 glycoprotein
molecules expressed on various APCs associated with β2-microglobulin [142]. Type I and II
NKT cells differ in the diversity of their TCRs and their known ligands. iNKT cells express
semi-invariant α/β TCRs consisting of an invariant Vα14/Jα18 chain in mice (Vα24/Jα18 in
humans; Figure 2) and a limited set of β chains [141]. Despite having well-characterized TCRs,
the endogenous ligands of iNKT cells are ill defined. Alpha-galactosylceramide (α-GalCer), a
synthetic glycosphingolipid (GSL) initially derived from a marine sponge, is the prototype
agonist of iNKT cells and a powerful tool in studying the impact of NKT cell activation on
microbial immunity [143]. In contrast to iNKT cells, type II NKT cells are nonresponsive to αGalCer and possess a more diverse TCR repertoire [140, 141]. NKT cells promptly secrete large
amounts of Th1 and Th2 cytokines including IFN-γ and IL-4, respectively, upon stimulation
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[144, 145], leading to the activation of macrophages, B cells, NK cells, and dendritic cells as
well as effector T cells (Figure 3). In addition to cytokine production, NKT cells also possess
cytotoxic effector activity by way of lysis of target cells that is dependent on perforin and FasL
[146, 147].
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Figure 2: Antigens and Receptors of invariant Natural Killer T (iNKT) cells.
iNKT cells have a semi-invariant T cell receptor (TCR) with restricted antigen-binding ability,
whereas conventional T cells possess diverse TCRs which can recognize a multitude of antigens.
iNKT cells bind glycolipid antigens presented in the context of an MHC Class I-like molecule
CD1d, in stark contrast to conventional CD4+ and CD8+ T cells which bind peptide antigens
presented in MHC Class II and I molecules, respectively.
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Figure 3: Factors released by invariant Natural Killer T (iNKT) cells.
iNKT cells rapidly release many cytokines and chemokines upon activation, which in turn have
regulatory effects on numerous effector cells of the innate and adaptive immune systems.
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Functional differences have been reported for NKT cells that differentially express CD4
[148, 149], NK1.1 [150-152] and other surface molecules [153] and may also exist between
NKT cells from different organs [154, 155]. There is no clear consensus on this issue, but it is
important to recognize that the composition and origin of NKT cells may affect their overall
response. For that reason, it is highly recommended that functional assays be assessed in context
of the origin and phenotype of NKT cells at the beginning and end of experiments.
1.4.2 NKT Cells in Experimental Animal Models
Various experimental models [156-161] have established NKT cells as the principal
initiators of an excessive pro-inflammatory response that promotes lethality in sepsis and
endotoxic shock. In mice, two consecutive injections of LPS stimulate NK1.1+ T cells [162] to
release large amounts of IFN-γ [163], which results in a lethal endotoxemia. LPS also activates
and increases the cytotoxicity of NKT cells in the liver through IL-12 produced by Kupffer cells
[164]. Additionally, when mice were depleted of NKT cells and NK cells by anti-NK1.1
antibody, the mice released less IFN-γ, and had reduced mortality when injected with LPS [156]:
a similar result was observed in mice deficient in Beta 2-microglobulin (β2m−/−) and lacking
most of their NK1.1+ αβ T cells [156]. iNKT cell-deficient (Jα18-/-) mice also had a significant
survival advantage when injected with LPS, with concurrently lower serum levels of IFN-γ [160]
and TNF-α than wild-type C57BL/6 mice [157]. While IFN-γ produced by iNKT cells facilitates
pathogen clearance [165], mortality remains unaffected [160], suggesting that the complete
activation of the pro-inflammatory cascade, which is important for the proper clearance of
infection, may have deleterious consequences when overly activated. In Jα18−/− mice injected
with LPS, NK cell activation and production of IFN-γ were also significantly reduced,
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suggesting a role for iNKT cells in amplifying the immune response by rapidly activating other
immune cell types [160].
In the cecal ligation and puncture (CLP) sepsis model, pre-treatment with monoclonal
antibody (mAb) blocking CD1d was shown to reduce CLP-induced mortality compared to IgGtreated controls and to suppress plasma and splenic levels of the Th2 cytokine IL-10 [166].
Although CD1d mAbs were thought to have enhanced Th1 responses [167, 168], these studies
looked at conditions in which there is deficient protective immunity by iNKT cells and examined
the ability of these antibodies to bypass iNKT activation and directly stimulate CD1d+ APCs.
Similarly, Jα18−/− mice were used to show that iNKT cell deficiency significantly decreased
septic mortality and ameliorated the systemic pro-inflammatory response [159].
Despite contradictory findings on the relative contribution of iNKT cells to a Th1 or Th2
response, these results consistently implicate a detrimental effect of NKT cell activation in
polymicrobial sepsis. These studies constitute growing evidence for the large contribution of
NKT cells to the dysregulated and overwhelming pro-inflammatory response in polymicrobial
sepsis and endotoxic shock. Although many strong correlations have been made between septic
mortality and NKT cell activation and cytokine production, researchers are still far from
delineating and demonstrating the exact mechanism by which NKT cells participate in the septic
immune response, or how their activity is regulated in general.
1.4.3 Mechanisms of iNKT Cell Activation
The mechanism by which iNKT cells are activated by microbial infection remains
unclear. A “direct” pathway, in which the TCR of iNKT cells recognizes the glycosphingolipid
cell-wall components of microbial pathogens such as Sphingomonas bacteria, has been reported
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[169]. This early activation of iNKT cells appears to be important for bacterial clearance,
because CD1d−/− and Jα18−/− mice were impaired in their ability to clear Sphingomonas [170].
Other studies have proposed a combination of two signals to culminate in IFN-γ secretion by
iNKT cells: a weak response that is initially generated from the recognition of CD1d-presented
endogenous glycosphingolipid antigens, followed by a stronger activation of the IL-12 receptor
on iNKT cells by APC-derived IL-12 [171, 172]. IL-12 alone cannot activate iNKT cells when
dendritic cells are absent, providing further evidence that recognition of self-ligand is an
essential part of this indirect pathway [171, 172]. In a third mechanism, iNKT cells may be
activated by IL-12 and IL-18 derived from APCs. In IL-12−/− and IL-18−/− mice, production of
IFN-γ by iNKT cells was impaired in response to LPS, although not completely abrogated [160].
The addition of recombinant IL-12 or IL-18 to iNKT cells was sufficient to induce a measurable
amount of IFN-γ production [160]. The addition of anti-CD1d Ab to co-cultures of iNKT cells
with DCs and LPS also did not affect IFN-γ production [160]. All these pathways may be active
during polymicrobial sepsis, due to the systemic release of many microbial stimuli, and may
form part of a positive feedback loop whereby IFN-γ produced by iNKT cells further activates
APCs [160]. Nevertheless, these mechanisms of iNKT cell activation quickly amplify the innate
immune response to infection and contribute to the rapid development of the hyperinflammatory
response in sepsis.
A remarkable and unique feature of iNKT cells is their ability to swiftly secrete copious
amounts of Th1- and Th2-type cytokines after stimulation without de novo cytokine mRNA
synthesis [173, 174]. iNKT cells contain preformed mRNA for these cytokines, which may
explain the rapidity with which they are secreted. Hence, they are believed to be responsible for
the first wave of cytokine release early in the course of immune responses, potentially shaping
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the course of subsequent adaptive responses. The paradoxical ability of iNKT cells to either
promote or suppress immune responses presents a classical “double-edged sword” dilemma of
immune regulation [175], which can be attributed at least in part to the ability these cells to
produce enormous quantities of Th1 cytokines, Th2 cytokines, or both.
Although natural killer (NK) cells are also known to be potent producers of IFN-γ and
play an important role in promulgating sepsis by migrating to the peritoneal cavity and
upregulating the pro-inflammatory activities of myeloid cells [176], studies have shown that
NKT cells rapidly activate NK cells to initiate the inflammatory process: administration of αGalCer rapidly activated NK cells to produce IFN-γ and upregulated their expression of the early
activation marker CD69 within hours of exposure [177]. This provides more evidence for the
pivotal role of NKT cells as a bridge between innate and adaptive immunity.
1.4.4 iNKT Cells in Human Populations
In mice, up to 30% of liver lymphocytes are NKT cells, but levels elsewhere are usually
0.1–1.0% [178, 179]. In humans, however, NKT cell frequencies are typically lower [180], and
can vary 100-fold between healthy individuals. In the thymus, iNKT cell frequencies are at least
100-fold lower in humans [179], whereas only 1% of hepatic lymphocytes are NKT cells [181].
While the tetramer binds NKT cells in mice and humans, human NKT cells can also be identified
with anti-Vα24 (or 6B11, an antibody specific for the CDR3 region of the TCRα chain used by
human NKT cells) and anti-Vβ11 [182, 183]: a reliable Vα14-specific antibody is not available
for mice.
As blood is often the only source of human NKT cells, findings are often extrapolated to
NKT cells in general. This is a risky assumption because the frequency and function of NKT
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cells from different organs may be unrelated [155, 180, 184]. In non-obese diabetic (NOD) mice,
for example, systemic NKT cell deficiencies are evident in all locations except blood [180]. It is
unclear whether a similar phenomenon exists for humans, but it cannot be assumed that blood
NKT cells are representative of NKT cells in other organs, even from the same donor.
Surprisingly, however, iNKT cells comprise 15% of hematopoietic cells obtained from human
omentum, the highest frequency of cells found to date within any organ in the human body: this
finding suggests that the omentum may play a key role in mediating immune-based responses to
intra-abdominal pathology [185].
1.4.5 iNKT Cells as Targets for Immunotherapy
Given the ability of NKT cells to bridge innate and adaptive immunity and their extensive
immunoregulatory roles, manipulation of these cells provides a promising therapeutic strategy
for sepsis and inflammation. α-Galactosylceramide (α-GalCer), the prototype iNKT cell
glycolipid ligand [186] has been used both experimentally and in several clinical trials in patients
with malignancies such as melanoma [187-189] and viral diseases [189, 190]. Depending on the
length and time of in vivo exposure to α-GalCer, iNKT cells may be strongly polarized towards a
Th1-like phenotype [158, 191] or a Th2-like phenotype [192, 193]. While the Th1 phenotype
appears to be mediated by dendritic cell (DC) maturation and its presentation of α-GalCer [158,
191], the Th2 phenotype, induced by repeated injection of α-GalCer, may be due to iNKT cell
anergy [194, 195]: iNKT cells may have a blunted response to DC stimulation with reduced
production of IFN-γ. Concomitant administration of α-GalCer and LPS protected mice from
sepsis [196, 197], and was associated with significantly lower serum levels of Th1 cytokines
(including IFN-γ and TNF-α), and higher levels of Th2 cytokines such as IL-10 [196, 197].
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Recent availability of several αGalCer analogs that exhibit distinct immunomodulatory
properties now allows for more comprehensive examination of iNKT cell function and the
consequences of their manipulation in transplant recipients (Figure 4). KRN7000, a synthetic
αGalCer, which selectively stimulates iNKT cells [186] and leads to the production of both pro(Th1) and anti-inflammatory (Th2) cytokines, has been used in several models of
allotransplantation. KRN7000 administration after γ irradiation and allogeneic bone marrow
transplantation was reported to reduce morbidity and mortality associated with murine graftversus-host disease in two independent studies [198, 199]. In contrast, treatment of cardiac
allograft recipients with KRN7000 failed to prevent rejection in a BALB/c-to-B6 model [200]. It
is possible that cytokine environments in which alloreactive T cells are primed in these models
may be different. Irradiation shifts the cytokine profile of iNKT cells towards a Th2-promoting
phenotype, which may contribute greatly to the beneficial effects of αGalCer in graft-versus-host
disease models [199, 201]. In comparison, Th1- and Th2-type cytokines concomitantly produced
after KRN7000 administration, may cancel each other out leading to no beneficial net effects in
the above cardiac allograft model or other similar conditions.

31

Figure 4: Select glycolipid agonists of iNKT cells.
From top to bottom, α-GalCer, OCH, and C20:2 are glycolipids which respectively skew the iNKT
cell response towards a Th1, Th2, and Th2 phenotype.
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OCH, a sphingosine-truncated analog of α-GalCer with known Th2-polarizing properties
[202] has exerted promising effects in the treatment of several experimental autoimmune
diseases [201, 203] where a destructive Th1-type response is suspected to play a role in the
disease pathogenesis: by ameliorating autoreactive T cells [188], OCH mitigated disease severity
in non-obese diabetic (NOD) mice [204] experimental autoimmune encephalomyelitis [202] and
collagen-induced arthritis (CIA) [205, 206]. Walker et al demonstrated that treatment with OCH
can not only prevent, but also cure disease symptoms in a humanized mouse model of
citrullinated fibrinogen-induced RA [207]. OCH also delayed Th1-mediated cardiac allograft
rejection in two mouse models [208].
Another promising Th2-biasing glycolipid is C20:2, a variant of α-GalCer consisting of a
fatty acyl side chain truncated from C26 to C20 that has two sites of unsaturation at carbons 11
and 14. C20:2 induces Th2-biased cytokine production [209] in vivo, and has a similar binding
affinity to CD1d as α-GalCer [210]. In vivo, C20:2 results in an overall reduced proinflammatory cytokine (IFN-γ) secretion, reduced iNKT cell expansion, and reduced activation
of T, B and NK cells [209, 211]. Its effects, however, do not last beyond six hours [209]. When
given in multiple doses, C20:2 significantly delayed and reduced the incidence of Type 1
Diabetes (T1D) in NOD mice [209, 211].
Tailoring the type of NKT cell stimulation to promote a pro- or anti-inflammatory
response has exciting implications for the future potential of NKT cell-based therapies for
various clinical conditions [212, 213]. Although more work is needed to determine what specific
factors trigger NKT cells to assume a Th1 or Th2-like phenotype during sepsis, the work done in
animal models so far provides insight on the contribution of NKT cells to inflammation and
injury, and an important foundation upon which to build a more targeted immunotherapy.
33

1.5 The Greater Omentum
1.5.1 Anatomy and Embryology of the Greater Omentum
The greater omentum has been identified as a rich source of iNKT cells in humans [185],
although little is known about its immune mechanisms. The greater omentum is a large fold of
visceral peritoneum that hangs down from the stomach, and drapes over much of the small
bowel, hanging as low as the pelvis [214]. Its descending and ascending portions fuse to form a
four-layer vascular fatty apron, with a space contiguous with the lesser sac. Several prominent,
hypertrophied folds within the greater omentum and adhesins between organs can be identified:
the gastrocolic ligament between the stomach and the transverse colon; the gastrosplenic
ligament that connects between the stomach and the spleen; and, occasionally, the splenorenal
ligament which adheres the spleen to the left kidney. The right and left gastroepiploic vessels,
which derive from the gastroduodenal and splenic arteries respectively, provide the blood supply
to the greater omentum. The greater omentum develops from the dorsal mesentery that connects
the stomach to the posterior abdominal wall. During gastric development, the stomach undergoes
a 90° clockwise rotation along the axis of the embryo, so that structures posterior to the stomach
are moved to the left, and anterior structures are moved to the right. As a result, the dorsal
mesentery folds over on itself, forming a pouch with its blind end on the left side of the embryo.
A second 90° clockwise rotation of the stomach along the frontal plane moves left-sided
structures inferiorly, and right-sided structures superiorly. Consequently, the blind-ended sac
(also called the lesser sac) formed by the dorsal mesentery is brought inferiorly, where it assumes
its final position as the greater omentum. The greater omentum subsequently enlarges to drape
over the majority of the small and large intestines.
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In the mouse, the greater omentum consists of a band of intra-abdominal adipose tissue
running from the distal spleen to the duodenal lobe of the pancreas [215, 216]. Murine and
human greater omenta share many micro-anatomical features despite some differences in gross
appearance [214]. In both, the omentum is a mobile structure that moves with gut peristalsis in a
small volume of intra-peritoneal fluid. This movement is thought to be essential for the omentum
to access injured or infected peritoneal surfaces where it adheres and facilitates repair processes:
as the “abdominal policeman,” the omentum restores order by surrounding the compromised site,
sealing microperforations, localizing inflammation, limiting the spread of infection, and
provoking revascularization and tissue regeneration [214, 215, 217]. Surgical transposition of
omental pedicles or flaps to injured body sites has been used for over a century for this purpose
[218, 219]. Because of the presence of peritoneal fluid, however, the omentum is also a common
location for neoplastic intraperitoneal seeding and infectious processes.
1.5.2 Histopathology of the Greater Omentum
The omentum in both mice and humans is composed of two mesothelial sheets enclosing
adipocytes embedded in loose connective tissue interspersed with islands of compact tissue,
known as “milky spots” [214, 220]. These spots contain macrophages, B cells, T cells, mast cells
and DCs [217], and are reactive structures that increase in size and number in response to
peritoneal inflammatory stimuli. Among the intra-abdominal adipose tissues, the greater
omentum is unique because it is thought to function in peritoneal surveillance and as an access
route for blood leukocytes entering the resting [221, 222] and inflamed [220] peritoneal cavity.
Milky spots develop a more organized structure where T and B cells segregate as in secondary
lymphoid tissues [223, 224]. This structural organization originally led to the proposal that milky
spots were themselves secondary lymphoid organs [224]. However, segregation of B and T cell
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areas was not observed in the resting omentum [223, 225]. These findings have led to the view
that the greater omentum is an inflammation-induced lymphoid structure that lacks the defining
characteristics of secondary lymphoid tissues, such as resident professional APCs, permanence
in basic structure, and segregation of B and T cell regions in the absence of antigenic stimulation
or inflammation.
1.5.3 Immunology of the Greater Omentum
Although controversy still exists around its precise immunological definition, the
omentum has been demonstrated to play an important role in both innate and adaptive immunity
[221, 226]. For example, the fetal omentum is critical to the development of B cells, and may
play an important role in the homeostasis of this cell population in adult mice and humans [227,
228]. In another study, the omentum was observed to contain large populations of stem cells
known as myeloid-derived suppressor cells (MDSCs) when mice were subjected to intraabdominal sepsis [229]: these cells secrete a variety of factors including those with
immunosuppressive functions and provide a regenerative microenvironment for injured tissues to
limit the area of damage and to mount a regenerative response [229]. Shah et al [229] suggest
that the presence of functional mesenchymal stem cells (MSCs) is a part of the mechanism by
which the omentum imposes tissue healing support on the damaged tissues. While expression of
stem cell markers and angiogenic growth factors were previously identified as contributing
factors to the regenerative properties of the omentum, Shah et al demonstrated that activated
omentum has at least two functionally distinct groups of cells that can facilitate regeneration of
damaged tissue: immunomodulatory CD45+Gr1+ MDSCs; and CD45− cells that have the ability
to suppress Th17 cells. A striking feature of the omentum is that, unlike secondary lymphoid
organs such as lymph nodes or spleen, it enlarges in response to foreign objects and acquires a
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large number of immunomodulatory cells along with cells with stem cell function. This type of
response has not been recognized for any other organ and is quite unique to the omentum.

1.6 Hypothesis
I hypothesize that expansion of the circulating iNKT cell population will occur in patients
with sepsis and severe sepsis. I further hypothesize that the administration of Th2-polarizing
glycolipid agonists of iNKT cells will significantly reduce sepsis severity by limiting the release
and subsequent production of pro-inflammatory Th1 cytokines.

1.7 Specific Objectives
I developed several specific objectives in order to test my hypotheses:
1) Prospectively evaluate the frequency and proportion of circulating iNKT cells in
patients admitted to the intensive care unit with sepsis, severe sepsis, or septic shock.
2) Develop and validate a mouse model of acute intra-abdominal sepsis that is
characterized by a marked pro-inflammatory response and leads to early mortality.
3) Assess the effect of Th1- and Th2-polarizing iNKT cell agonists on sepsis severity in
the animal model of sepsis.
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Chapter 2: Materials and Methods
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2.1 Ethics
All animal experimentation was carried out in strict accordance with the
recommendations and guidelines established by the Canadian Council on Animal Care as well as
institutional regulations. The protocols were approved by the Western University Animal Care
and Veterinary Services (Approval number: 2008-034-01).
For the study involving human subjects, approval of the study protocol for both the
scientific and ethical aspects was obtained from the Western University Research Ethics Board
for Health Sciences Research Involving Human Subjects (Approval number: REB103036).

2.2 Mice
Female C57BL/6J (B6) mice, 10–14 weeks of age, were purchased from Charles River
Canada Inc. (St. Constant, Quebec, Canada). J18−/− mice, which lack iNKT cells [230], were
based on a B6 background and obtained from Dr. Luc Van Kaer (Vanderbilt University,
Nashville, TN, USA). The development of the lymphoid organs in J18−/− mice is
macroscopically normal, and the numbers of total lymphocytes are not significantly different
from Jα18+/+ mice with the exception of a complete loss of the Vα14 NKT subpopulation of
NKT cells [230]. GFP-expressing transgenic mice are B6 mice with omnipresent enhanced GFP
expression under the β-actin promoter, and were kindly provided by Dr. Stephen Kerfoot
(Western University, London, Ontario) for a limited number of experiments.
Animals had an average weight of 22.5 g (range, 21-25 g) prior to the start of the
experiments. Animal husbandry conditions included a room temperature of 23°C, humidity of
50%, and a 12-hour light-dark cycle (dark from 1900h to 0700h). Bedding in cages consisted of
sawdust and wood shavings, while corn mash and water (in a stoppered-bottle with a nose-
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activated nozzle) was available for mice to feed ad libitum. Cages also contained an igloo to
allow nesting. Animals were housed with one to three cage mates, and were allowed to adapt to
laboratory conditions for at least 3 days prior to experiments.

2.3 Mouse Intra-abdominal Sepsis Model
2.3.1 Preparation of Fecal Slurry
The solution used to cause IAS was made by the following procedure: fresh feces were
collected from the lower cecum of euthanized donor mice, weighed, and mixed with a calculated
volume of saline solution to give a fecal concentration of 90 mg/mL. To ensure reproducibility,
the procedure was standardized by the use of fresh solution prepared from mice living in the
same conditions as the experimental animals. The fecal solution (FS) was pressed through a 70μm nylon mesh strainer (BD Biosciences, Franklin, NJ) to remove particulate matter.
2.3.2 Induction of Sepsis
For sepsis induction, each mouse was given an intraperitoneal (i.p.) injection of 0.5 mL
of FS using a syringe and 27G needle (4 mg of FS per 1 g body weight). Sham mice were
injected with sterile normal saline (NS). Pain (either from the injection or from FS) was assessed
using facial expression as described by Langford et al [231], as well as body posture and
vocalization. Analgesia was provided by a subcutaneous injection of buprenorphine (0.1mg/kg).
2.3.3 Monitoring of Mice
Monitoring of the health of the animals was conducted by two investigators every 2 hours
after the induction of sepsis for 12 hours, and then every hour thereafter: one of the investigators
was blinded to the treatment. Mice were evaluated while they were still in their cages (with the
lids removed for better visualization).
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2.3.4 Euthanasia of Mice
At the conclusion of the experiments, animals were sacrificed and post-mortem
laparotomy was performed in order to collect tissues. Mice were anesthetized with 100 mg/kg
ketamine (Bioniche Life Sciences, Belleville, ON) and 5 mg/kg xylazine (Bayer AG,
Leverkusen, Germany), and euthanized by cardiac puncture using a 27G needle and 3-mL
syringe.

2.4 Development of the Murine Sepsis Score
In this project, a scoring system (the murine sepsis score, MSS) was developed to assess
and monitor disease severity, and serve as a humane surrogate to death as an endpoint. In a pilot
study involving thirty mice that were given 90 mg/mL FS and observed over 24 hours, a
veterinarian from the Animal Care and Veterinary Services (Ian Welch, ACVS, Western
University), and two researchers from our group assessed the mice jointly using variables that
have been described in the literature [231-233]. Certain variables such as temperature and weight
loss did not change during the experimental timeline, while fewer than 5% of mice needed
analgesia for pain immediately after the fecal slurry injection. Consequently, the final variables
that were incorporated into the MSS (Table 5) included spontaneous activity, response to touch
and auditory stimuli, posture, respiration rate and quality (laboured breathing or gasping), and
appearance (i.e. degree of piloerection). Each of these variables are given a score between 0 and
4 (Table 5). Mice were euthanized if the MSS at any given time point was greater than 21, or if
the points ascribed to respiratory rate or quality increased by more than 3.
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Table 5: Murine Sepsis Score (MSS)
Appearance
01234-

Coat is smooth
Patches of hair piloerected
Majority of back is piloerected
Piloerection may or may not be present, mouse appears “puffy”
Piloerection may or may not be present, mouse appears emaciated

Level of consciousness
01234-

Mouse is active and moving
Mouse is moving but avoids standing upright
Mouse is slow moving
Mouse is not moving without provocation
Mouse does not move even when provoked

Response to stimulus
01234-

Mouse responds immediately to auditory stimulus or touch
Slow or no response to auditory stimulus, responsive to touch
No response to auditory stimulus, moves away in response to touch
No response to auditory stimulus, some movement in response to touch
No response to auditory stimulus, little or no movement in response to touch

Activity
01234-

Mouse is any of: eating, drinking, climbing, running, fighting
Mouse is moving around bottom of cage
Mouse is stationary with occasional investigative movements
Mouse is stationary
Mouse experiencing tremors, particularly in the hind legs

Eyes
01234-

Open
Eyes not fully open, possibly with secretions
Eyes at least half closed, possibly with secretions
Eyes half closed or more, possibly with secretions
Eyes closed or mily

Respiration rate
01234-

Normal, rapid mouse respiration
Slightly decreased respiration (rate not quantifiable by eye)
Moderately reduced respiration (rate at the upper range of quantifying by eye)
Severely reduced respiration (rate easily countable by eye, 0.5s between breaths)
Extremely reduced respiration (> 1s between breaths)

Respiration quality
01234-

Normal
Brief periods of laboured breathing
Laboured, no gasping
Laboured with intermittent gasps
Gasping
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2.5 Glycolipids
Lyophilized OCH was generously supplied by the National Institutes of Health (NIH)
Tetramer Core Facility (Atlanta, GA, USA). Each vial containing 0.2 mg of OCH was
solubilized in 1 mL of sterile distilled water and stored as aliquots at 4°C until use. KRN7000
was synthesized, solubilized at 1 mg/ml in dimethylsulfoxide (DMSO) and stored as aliquots at
−20°C until use [234]; the control vehicle was 2% DMSO in phosphate-buffered saline (PBS).
C20:2 was synthesized as described previously [235] and dissolved in a vehicle solution
containing PBS, 0.02% Tween 20, and 0.1% DMSO. The resulting stock solution was stored in
aliquots at −20 °C. Aliquots were re-warmed and sonicated prior to use. For in vivo experiments,
mice were injected i.p. with a single dose of glycolipid (4 µg/dose) [209]. In experiments where
mice were induced with IAS, glycolipids were administered 15-20 minutes after the injection of
fecal slurry to allow the animals to recover in between injections.

2.6 Antibodies
2.6.1 Mouse
Allophycocyanin (APC)-conjugated PBS-57-loaded and -unloaded CD1d tetramers for
staining mouse iNKT cells were provided by the NIH Tetramer Core Facility (Emory University,
Atlanta, GA, USA) [209]. Fluorescein isothiocyanate (FITC)-conjugated anti-TCR-β (H57-597)
and phycoerythrin (PE)-conjugated anti-CD69 (H1·2F3) monoclonal antibodies (mAbs) were
purchased from eBiosciences (San Diego, CA, USA) or BD Biosciences (Mississauga, ON,
Canada). PE-conjugated anti-B220/CD45R and anti-CD8 mAbs, as well as FITC-conjugated
anti-CD3 mAbs were purchased from BD Biosciences (Table 6).
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2.6.2 Human
APC-conjugated PBS-57-loaded and -unloaded CD1d tetramers for staining human iNKT
cells were provided by the NIH Tetramer Core Facility (Emory University, Atlanta, GA, USA)
while FITC-conjugated anti-CD3 (SK7), PE-conjugated anti-CD56 (B159), and peridinin
chlorophyll protein complex (PerCP)-conjugated anti-CD56 were obtained from BD Biosciences
(Table 6).
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Table 6: Antibodies used for flow cytometry in mouse and human studies.
Species

Target

Fluorochrome

Identifies

Source

Volume
(µL)

Mouse

CD3

APC

T Cells

eBiosciences

1

CD45R (B220)

APC

B Cells

eBiosciences

1

TCRβ

FITC

T Cells

eBiosciences

1

NK1.1

PE

NK and NKT

eBiosciences

1

NIH

1

Cells
CD1d tetramer-

APC

Control for iNKT

PBS-57 unloaded
CD1d tetramer-

Cells
APC

iNKT Cells

NIH

1

APC

Macrophages

eBiosciences

1

-

Dead cells

Life

0.5

PBS-57 loaded
F4/80
Anti 7-AAD

Technologies

Human

Annexin V

FITC

Apoptotic Cells

eBioscience

2.5

CD3

FITC

T Cells

eBioscience

1

Vα24

PE

iNKT Cells

NIH

1

APC

Control for iNKT

NIH

1

CD1d tetramerPBS-57 unloaded
CD1d tetramer-

Cells
APC

iNKT Cells

NIH

1

PE

NK and NKT

eBioscience

1

PBS-57 loaded
CD56

Cells
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2.7 Bacterial CFU Counts
2.7.1 Tissue Homogenization for CFU
Whole hearts, lungs, and kidneys (left and right) were removed from euthanized mice,
taking care to dissect away lymph nodes, and homogenized in 5 mL of PBS. Homogenates were
serially diluted 1:10 in PBS and plated on bovine heart infusion (BHI) agar. Plates were grown
aerobically at 37° overnight to determine tissue CFU.
2.7.2 Peripheral Blood CFU Determination
10 µL of intra-cardiac blood was collected in a syringe from the right ventricle during
euthanasia and cardiac puncture, serially diluted 1:10 with PBS, and plated on BHI agar to
determine blood CFU.

2.8 Preparation of mouse hepatic, splenic, and omental cell suspensions
To obtain hepatic lymphoid mononuclear cells, mice were euthanized, and livers were
flushed with sterile PBS before they were harvested and pressed through a 40-µm nylon mesh.
The resulting homogenate was washed in cold PBS, resuspended in a 33.75% Percoll PLUS
solution (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and spun at 700 × g for 12 min at
room temperature. The pelleted cells were then treated with ACK lysis buffer to remove
erythrocytes and washed in cold PBS prior to staining.
To obtain omental lymphoid mononuclear cells, mice were euthanized, and the spleens,
pancreas, and omenta were removed en-bloc and suspended in ice-cold PBS. The omenta floated
above the spleen-pancreas complex and were removed and processed similar to the liver, as
described above. Spleens were processed with a tissue homogenizer, and the resulting
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homogenate was washed in cold PBS. The pelleted cells were treated with ACK lysis buffer for
4 minutes to remove erythrocytes, and washed in cold PBS prior to staining.

2.9 Adoptive Transfer of iNKT Cells into Jα18-/- Mice
Hepatic mononuclear cells and splenocytes were isolated, as previously described, from
GFP-expressing transgenic mice. CD4+ T cell populations were obtained using EasySep® Mouse
CD4+ T cell enrichment kit (Stem Cell Technologies, Vancouver, British Columbia, Canada) as
per manufacturer’s instructions. iNKT cells were further enriched by sorting with anti-TCRβ and
CD1d tetramer on a FACSAriaIII flow cytometric cell sorter (London Regional Flow Cytometry
Facility, London, Ontario). Cell populations were used only when purity was >95% as
determined by flow cytometry. For the adoptive transfer experiments, 5 × 105 iNKT cells were
transferred i.v. into Jα18−/− mice. Twelve hours after the transfer, mice were given IAS and
monitored as already described.

2.10 Flow Cytometry
Mouse hepatic, splenic, and omental cells (1 × 106), and human peripheral blood
mononuclear cells (PBMCs) and omental cells (1 × 106) were placed in fluorescence activated
cell sorter (FACS) tubes (BD Biosciences, San Jose, CA, USA), and washed with cold FACS
buffer [PBS + 2% fetal bovine serum (FBS) + 0.1% sodium azide]. Mouse cells were incubated
with 5 µg/ml anti-mouse CD16/CD32 mAb (clone 2·4G2, Fc-block, eBiosciences) for 20 min on
ice before staining with fluorescent mAbs or tetramer diluted in FACS buffer at 4°C for 30 min.
Human cells were stained with fluorescent mAbs or tetramer diluted in FACS buffer at 4°C for
40 min.
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Cells were then washed and flow cytometry was performed using FACSCanto II and
FACSDiva software. Analyses were conducted using FlowJo software (Treestar, Ashland, OR,
USA). The gating strategy used for analysis of apoptotic cells is shown in Figure 5.
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Figure 5: Gating strategy to identify the percentage of apoptotic and necrotic immune cell
populations.
CD3-APC (for the detection of T cells) is shown as an example, but the same strategy was used
for macrophages (F480-APC), B cells (B220-APC), and Natural Killer (NK) cells (NK1.1-PE).
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2.11 Enzyme-Linked Immunosorbent Assay (ELISA)
Mouse IL-4 and IFN-γ ELISA kits were purchased from eBioscience, and were used to
assess serum from experimental animals. Kits were run as specified by the manufacturer in
Costar ELISA plates (Immunohistochemistry Technologies, Bloomington, MN). Plates were
read at OD450 and at the reference OD570.

2.12 Multiplex Cytokine Analysis
Serum was analyzed by bead-based multiplex assay for 32 different cytokines,
chemokines, and growth factors (Eve Technologies, Calgary, Alberta, Canada) including
granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating
factor (GM-CSF), interferon-gamma (IFN-γ), interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-9, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, IP-10, keratinocyte
chemo-attractant (KC), leukemia inhibitory factor (LIF), lipopolysaccharide-induced CXC
chemokine (LIX), monocyte chemotactic protein (MCP)-1, monocyte-colony stimulating factor
(M-CSF), monokine induced by gamma interferon (MIG), macrophage inflammatory protein
(MIP)-1α, MIP-1β, MIP-2, Regulated on Activation, Normal T cell Expressed and Secreted
(RANTES), tumour necrosis factor (TNF)-α, and vascular endothelial growth factor (VEGF).
Multiplex data was visualized using a cytokine heat map that was generated using the
web-based program Matrix2png [236]. The mean for each row of cytokine values was set at 0
with white representing values greater than 0, and brown lower than 0.

2.13 Serum Biochemistry
Serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and
lipase, expressed as U/L, as well as creatinine (expressed as mg/dL), glucose (mg/dL), and
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albumin (expressed as mg/dL) were estimated using a commercially-available diagnostic kits
(Catachem Inc., Oxford, CT) according to the manufacturer’s instructions.

2.14 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA was isolated from hepatic, splenic, and omental tissues using the TRIzol
reagent (Invitrogen, Burlington, Ontario) and resuspended in nuclease-free water (Invitrogen).
Quality control of samples was carried out using a Nanodrop ND-1000 spectrophotometer.
cDNA was prepared using 1000ng of RNA by Superscript III RNase H- Reverse Transcriptase
with oligo dT priming (Invitrogen). Quantitative real-time PCR reactions were carried out in
triplicate from every transcription reaction using the ABI Prism 7900HT apparatus (Perkin
Elmer) with Taqman (Invitrogen) probes. The sequences of the primers and Taqman probes
(Invitrogen) used in this study were as follows (GenBank Accession number S75451.1)[178]:
Vα14: 5’−TGGGAGATACTCAGCAACTCTGG−3’; Jα18:
5’−CAGGTATGACAATCAGCTGAGTCC−3’; Vα14 Probe FAM: 5’−FAMCACCCTGCTGGATGACACTGCCAC-TAMRA−3’. Quantitative analysis was performed by
ΔΔCt method by using the Taqman GAPDH Gene Expression Assay (Invitrogen) as an internal
control. The sequence that was examined for design of quantitative primers was 5’GATGCTAAGCACAGCACGCTGCACATCACAGCCACCCTGCTGGATGACACTGCCAC
CTACATCTGTGTGGTGGGGG//ATAGAGGTTCAGCCTTAGGGAGGCTGCATTTTGGAG
CTGGGACTCAGCTGATTGTCATACCTGA-3’ (// refers to the exon-splice site between Vα14
and Jα18 segments of the invariant TCR). Annealing temperatures for the primer-probe sets were
at 60ºC for both the invariant TCR and GAPDH.
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2.15 Histology
2.15.1 Organ Isolation
Mice were euthanized as described above. Organs were surgically removed without tool
marks and were placed in 10-volumes of fresh 10% neutral buffered formalin (BDH, VWR,
West Chester, PA, USA).
2.15.2 Histology Tissue Processing
Soft tissues (spleen, liver, intestine, peritoneum, and omentum) were further fixed in
formalin for 48 hours at 4°C, changed daily. Organs were rinsed in 1 PBS before being resuspended in 10-volumes of 1 PBS twice a day for three days, and washed in 10-volumes of
70% ethanol twice and stored in 70% ethanol until processed. Fixed tissues were placed in 4 mm
Fisherbrand TRU-Flow tissue cassettes. Formalin-fixed cassetted tissues in 70% ethanol were sent to
The Robarts Research Institute Molecular Pathology Core Facility for processing in preparation for
embedding in wax. Cassettes were processed in Leica ASP300 fully enclosed paraffin wax tissue
processor overnight and were transferred into a warm wax bath and embedded in paraffin wax.
Embedded tissues were stored at room temperature until sectioning.
Tissues were sectioned on a microtome HM335E Microtome Leica in the Robarts Research
Institute Molecular Pathology Core Facility using MB35 Premier Microtome blades (Thermo
Scientific) into 5 micron sections. Serial sections were collected for head sections, and representative
sections were cut for the spleen. Sections were mounted on Fisherbrand Superfrost Plus microscope
slides (Fisher Scientific, Fair Lawn, NJ, USA) and were dried at 45°C for 48 hours prior to
storage/staining.
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2.15.3 Haematoxylin and Eosin Staining of Processed Tissue
Tissues were stained with haematoxylin and eosin in a Leica Autostainer XL. Slides were
allowed to dry and Fisher Finest Premium Cover Glass (Fisher Scientific, Fair Lawn, NJ, USA)
cover slips were affixed to the slides using Cytoseal 60 low viscosity mounting medium
(Richard-Allen Scientific, Kalamazoo, MI, USA). Cover-slipped slides were dried for at least 24
hours horizontally before vertical storage.
2.15.4 Terminal Deoxynucleotidyl Transferase dUTP Nick End Labelling (TUNEL) Assay
This procedure was performed manually as described previously [237]. Briefly, 4-µm
sections were deparaffinized in xylenes, rehydrated in graded alcohols, and rinsed in distilled
water. Antigen unmasking was accomplished using freshly prepared Proteinase K solution (10
μg/mL) for 60 min at 37°C. After washing twice with distilled water, sections were incubated
with TdT enzyme (75 U/mL) and digoxigenin-11-UTP (5 nmol) for 90min at 37°C. The slides
were then washed in SSC buffer (150 mmol NaCL, 15 mmol sodium citrate, pH 7.0), followed
by Tris-HCl buffer (10 mmol in 150 mmol NaCl, pH 8.2) for 1 min per wash. A blocking agent
was used to prevent non-specific binding and sections were developed with a Fab fragment
against digoxigenin linked to alkaline phosphatase and fast red chromogen. Sections were then
washed and counter stained.
2.15.5 Histopathological Evaluation
Slides were evaluated in collaboration with two pathologists (Drs. Aaron Haig and Ian
Welch, Department of Pathology, Western University, London, Ontario). After all slides were
observed, evaluation criteria were determined for each tissue type. The relative number of
lymphocytes present, the presence of cell necrosis and apoptosis, and other factors relating to
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inflammatory change were assessed. The presence and severity of these findings were used to
determine differences in histological pathology in the mice.

2.16 Patients
2.16.1 Inclusion Criteria
Patients aged 18 years and older with a diagnosis of severe sepsis or septic shock upon
admission to the Medical-Surgical Intensive Care Unit (MS-ICU) at London Health Sciences
Centre-University Hospital (LHSC-UH) and the Critical Care and Trauma Centre (CCTC) at
London Health Sciences Centre-Victoria Hospital (LHSC-VH) were prospectively recruited
from July 2012 to December 2012. The first day following ICU admission was considered day 1
in the analysis. Sepsis was defined as suspected infection in the presence of two or more
systemic inflammatory response syndrome criteria [15]. Severe sepsis was defined as sepsis plus
sepsis-induced organ dysfunction or tissue hypoperfusion [15]. Sepsis-induced hypotension was
defined as systolic blood pressure (SBP) < 90 mmHg, mean arterial pressure < 70 mmHg or SBP
decrease > 40 mmHg or < 2 SD below normal for age in the absence of other causes of
hypotension. Septic shock was defined as hypotension (SBP < 90 mmHg) despite adequate fluid
resuscitation (> 1,500 ml) or the use of vasoactive agents [15]. Severity of illness was assessed
on the basis of two scores: the Acute Physiology and Chronic Health Evaluation II (APACHE II)
score (Table 7) for the first 24 hours following diagnosis [238, 239]; and the Mannheim
Peritonitis Score (Table 8) for patients with intra-abdominal sepsis [240].
To calculate the APACHE II score, twelve common physiological and laboratory values
(temperature, mean arterial pressure, heart rate, respiratory rate, oxygenation (PaO2 or A-aDo2),
arterial pH, serum sodium, serum potassium, serum creatinine, haematocrit, white blood cell
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count and Glasgow Coma Score) are marked from 0 to 4, with 0 being the normal, and 4 being
the most abnormal (Table 7). The sum of these values is added to a mark adjusting for patient
age and a mark adjusting for chronic health problems (severe organ insufficiency or
immunocompromised patients) to arrive at the APACHE II score.
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Table 7: APACHE II Scoring System
Variable
Temperature
(°C)
Mean
Arterial BP
(mm Hg)
Heart Rate
(min-1)
Respiratory
Rate (min-1)
A-aPO2 (if
FiO2>50%)
PaO2 (if
FiO2<50%)
Arterial pH

+4

+3

+2

+1

0

+1

+2

+3

+4

≥ 41

39-40.9

38.538.9

36-38.4

34-35.9

32-33.9

30-31.9

≤ 29.9

≥160

130-159

110-129

70-109

50-69

≥ 180

140-179

110-139

70-109

55-69

≥ 50

35-49

≥ 500

350-499

25-34
200-349

12-24

7.6-7.69

40-54

≤ 39
≤5

6-9

< 200
> 70

≥ 7.7

10-11

≤ 49

7.5-7.59

Serum
≥ 52
41-51.9
32-40.9
HCO3Serum Na+
≥ 180
160-179 155-159 150-154
(mmol/L)
Serum K+
≥7
6-6.9
5.5-5.9
(mmol/L)
Serum
≥ 3.5
2-3.4
1.5-1.9
Creatinine
(g/dL)
Hematocrit
≥ 60
50-59.9
46-49.9
WBC Count
≥ 40
20-39.9
15-19.9
Age (y)1
1
ADD: 5 points if age is 65-74 yrs; 6 points if age >75 yrs

61-70

55-60

< 55

7.337.49
23-31.9

7.257.32
18-21.9

7.157.24
15-17.9

< 7.15

130-149

120-129

111-119

≤ 110

3.5-5.4

3-3.4

2.5-2.9

0.6-1.4

< 0.6

30-45.9
3-14.9
< 44

20-29.9
1-2.9
45-54

< 15

< 2.5

< 20
<1
55-64

Chronic Health Adjustment:
ADD: 2 points if patients have had elective surgery or for non-surgical patients. 5 points for emergency surgery
1.

Biopsy-proven cirrhosis

2.

New York Heart Association Class IV Congestive Heart Failure

3.

Severe COPD (hypercapnic; requiring home O2; pulmonary hypertension)

4.

Chronic dialysis

5.

Immune-compromised (HIV; immunosuppressive medications)

APACHE II score is calculated by adding all the points accumulated by a patient in the first 24 hours of his/her
admission to the ICU.
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Table 8: Mannheim Peritonitis Score (MPI)
Variable
Score
Age > 50 years
5
Female gender
5
*
Organ failure
7
Malignancy
4
Pre-operative duration of peritonitis > 24 hours
4
Origin of sepsis not colonic
4
Diffuse generalized peritonitis
6
Exudate
6
Clear
0
Cloudy or purulent
6
Feculent
12
*
Definitions of organ failure: Kidney: creatinine >177 µmol/L, urea > 167 µmol/L, oliguria < 20
mL/h; Lung: pO2 < 50 mmHg; pCO2 > 50 mmHg; Shock: hypodynamic or hyperdynamic;
Intestinal obstruction (only if profound): Paralysis > 24h or complete mechanical ileus
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2.16.2 Exclusion Criteria
Exclusion criteria were the presence of immunodeficiency or concomitant
immunosuppressive therapy, pregnancy, Do Not Resuscitate (DNR) status and cardiac arrest.
Informed consent was obtained directly from each patient or his or her legal representative
before enrolment.

2.17 Microbiological Diagnostics
Standard cultures in biological samples guided by the presumptive source of the septic
insult were performed to assess the presence of bacterial and fungal infection. Species
identification and biotyping was conducted by matrix-assisted laser desorption ionization–time
of flight mass spectrometry (MALDI-TOF MS; MALDI Biotyper, Bruker Daltonics, Germany).
Potentially contaminant microorganisms were not considered.

2.18 Isolation and Staining of Leukocytes from Human Peripheral Blood
Human blood was collected in heparinized vacuum tubes, diluted 1:1 with RPMI, layered
over pre-warmed Ficoll and spun at 700 × g for one hour. PBMCs were removed by pipetting and
washed in 40 ml of warm RPMI, pelleted for 5 minutes at 700 × g, and resuspended in cRPMI. Cells
were assessed for viability by trypan blue. Cells were then washed and stained with anti-CD3ε-

FITC (clone HIT3a, BD Pharmingen) and anti-CD69-PE (clone FN50, eBioscience) mAbs,
along with human CD1d tetramer.

2.19 Statistical Analysis
All data were maintained in Microsoft Excel 2010 (Microsoft, Redmond, WA), and were
analyzed using Graphpad Prism Version 5.01 (Graphpad, La Jolla, California). In all analyses,
two-tailed P values less than 0.05 were considered statistically significant.
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For murine experiments, statistical comparisons were performed using analysis of
variance (ANOVA) or Mann-Whitney U test where appropriate. Survival curves were calculated
by the Kaplan-Meier method.
Each of the seven variables measured as part of the MSS consisted of five possible scores
(0 to 4). The internal consistency of the MSS and each of the variables was assessed by
Cronbach’s alpha. Inter-rater reliability of the MSS was also assessed by calculating the
intraclass coefficient (ICC), comparing each assessor’s independent scores for each mouse
(sham and septic) at 2, 12, 14, 16, 18, 20, and 24 hours. Additionally, the ability of the MSS to
discriminate between sham and septic mice was tested using the receiver operating characteristic
(ROC) curve, and by quantifying the area under the curve (AUC) [241]. An AUC between 0.7
and 0.8 is classified as “acceptable,” and an AUC between 0.8 and 0.9 is considered to have an
“excellent” discrimination [241]. For the MSS, the score giving the best Youden index was
determined to be the cutoff point [242]: the sensitivity, specificity, and positive and negative
predictive values were calculated based on this score. To ensure that the MSS reflected the
severity of the septic insult, correlations between the sepsis score and serum pro-inflammatory
cytokine levels were performed by calculating the Pearson correlation coefficient (Pearson’s r)
with 95% confidence intervals.
Biochemistry and cytokine data obtained at all the time points for sham mice were pooled
together and employed as a common control group, as Friedman’s test indicated no differences
over time. Data obtained from mice with IAS were considered independently. Differences
between groups were analyzed by applying non-parametric ANOVA (Kruskal-Wallis) tests,
followed by post-hoc pairwise multiple comparisons by Dunn’s method. For cytokine analyses,
data from multiple experiments were pooled and analyzed by one-way ANOVA with post-hoc
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comparisons using Tukey’s tests. Group sizes reported for data varied over time, reflecting the
mortality rate in septic animals.
For human subjects, differences between groups were assessed using the Mann–Whitney
U-test or Chi-square test for continuous and categorical variables, respectively. Survival curves
were calculated by the Kaplan-Meier method.
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Chapter 3: Results
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3.1 Peripheral blood iNKT cells are elevated in patients with sepsis/severe
sepsis
We first sought to determine if patients with sepsis had an altered frequency of iNKT
cells in their peripheral blood compared to non-septic patients. We prospectively evaluated thirty
patients who were admitted to the London Health Sciences Centre (LHSC) Critical Care and
Trauma Centre (CCTC) for sepsis or non-sepsis-related critical illness; 23 patients were
diagnosed with sepsis/severe sepsis, while 7 patients were non-septic trauma patients (Table 9).
In the non-septic group, 3 patients (43%) had sustained traumatic head injuries and 4 patients
(57%) had emergency surgery for trauma (2 liver resections; 1 abdominal aortic surgery; 1 spine
stabilization operation). Groups were similar in age and severity of illness, as calculated by the
APACHEII score [238]. However, the gender distribution was significantly different between the
two groups, with a preponderance of males in the non-septic group (p< 0.0001). Most of the
patients in the septic group had intra-abdominal sepsis (44%) or lower respiratory tract infections
(39%) as confirmed by diagnostic tests. In 30% and 17% of septic patients respectively, a single
Gram-positive or Gram-negative pathogen was identified, while multiple organisms were
identified in 30% of the septic group. In 17% of septic patients, the microbial agent was not
identified, while 1 patient (4%) had fungal candidemia (Table 9).
When lymphocyte subpopulations were assessed by flow cytometry and compared, the
septic group had a higher median percentage of T cells among total lymphocytes (57.8% versus
36.7% in the non-septic group, p= 0.039) (Table 10; Figure 6a and b). Moreover, the iNKT:T
cell ratio was significantly higher in the septic group (Table 10). Patients in the septic group
stayed in hospital for a significantly longer time (25.2 days versus 12.8 days, p= 0.045 by Mann
Whitney U test), although in-hospital mortality was similar between the two groups (Table 10).
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Table 9: Demographics and clinical characteristics of study patients
Demographic and clinical characteristics
Median Age (years)
Gender

Non-septic
(n = 7)
61

Septic
(n = 23)
59

6
1
23

13
10
16

4
1
0
2
1
3
1
2

4
7
0
4
1
7
4
1

-

14
4
0

-

-

6
1
9
0
2
0
0
0

-

-

5
4
1
4
4

-

Male
Female
Mean APACHEII Score
Comorbidities, n:
Cardiovascular Disease
COPD
Chronic Renal Failure or Dialysis
Diabetes mellitus types 1 and 2
Alcohol abuse
Hypertension
Neoplasia
Obesity
Diagnostic at ICU admission, n:
Sepsis
Severe Sepsis
Septic Shock
Presumed Source of Infection, n:
Lower respiratory tract/pneumonia
Urogenital
Intra-abdominal
Catheter- or device-Related
Skin (soft tissues)
Prosthesis
Central nervous system
Other/unknown
Documented microbial agent, n:
Gram-positive
Gram-negative
Fungi
Polymicrobial
None/Unknown
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P Value
0.433
< 0.0001

0.377
0.689

Table 10: Outcomes of study patients.
Variable
Median White Blood Cell Count
Lymphocytes, %1
Lymphocyte Subset Populations2
T cells, %
NK cells, %
NKT cells, %
NKT:T cell ratio, %
iNKT cells, %
iNKT:T cell ratio, %
Mean Hospital Stay (range), days
Mortality, n (%)
Cause of Mortality, n (%)
Multi-organ failure
Cardiac arrest
Withdrawal of care

Non-Septic
(n = 7)
10.6
16.2

Septic
(n = 23)
11.5
17.6

P Value

36.7
5.19
0.45
0.011
0.0041
0.0090
12.8 (0-38)

57.8
12.25
1.88
0.029
0.00569
0.020
25.2 (4-55)

0.039
0.274
0.262
0.274
0.138
0.047
0.045

3 (43)

5 (28)

0.955
0.293

1 (14)
1 (14)
1 (14)

4 (17)
0 (0)
1 (4.3)

1

Expressed as a percentage of the total sample analyzed on flow cytometry

2

Expressed as a percentage of lymphocytes. Median populations are presented.
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0.182
0.252

Figure 6: Characterization of iNKT cell populations in the sera of critically-ill patients.
(a) Representative flow cytometry plots of peripheral blood sampled from a septic and non-septic
patient. (b) Histograms (median ± SEM) comparing frequency of T cells, NK cells, and iNKT:T
cell ratios in septic and non-septic patients in the intensive care unit. *p< 0.05 by Mann Whitney
U test (C) Kaplan-Meier survival curves from time of blood collection to time of discharge.
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3.2 Validation of the MSS in a mouse model of IAS
We next sought to validate the MSS as a humane and effective surrogate to death as an
endpoint in our mouse model of IAS, and correlate it with disease severity. A total of 300 mice
were used in all the experiments that were conducted independently over a period of two years,
to develop the mouse model of IAS and the MSS, and to validate the latter. Compared to shamtreated mice (n= 60), which had a survival of 100% throughout the experimental timeline, mice
with IAS had a survival rate of 0% for 180 mg/mL FS (n= 20), 25% for 90 mg/mL FS (n= 200)
and 40% for 45 mg/mL FS (n= 20) at 24 hours post-FIP induction (Figure 7A). For subsequent
experiments, we used a FS concentration of 90 mg/mL to mimic the clinical mortality of 70-80%
in severe untreated intra-abdominal sepsis [243, 244]: MSS for FIP mice at this concentration are
shown in Figure 7B. Compared to sham-treated mice with a mean score of 1 after 24 hours, FIPtreated mice had significantly higher (p <0.0001) sepsis scores. Between 0 to 11 hours post-FIP
induction, mouse scores remained relatively consistent as assessed by independent observers,
with mild piloerection and decreased movement. After 12 hours, septic mice appeared to
progressively manifest additional symptoms including decreased respiratory rate, increasingly
laboured breathing and minimal response to auditory and tactile stimuli. Between 12 to 17 hours
post-FIP induction, variability in sepsis severity scores was observed to be due to differences in
respiratory rates and quality of breathing as well as response to tactile and auditory stimuli. The
intra-class correlation coefficient for comparison between the blinded and non-blinded assessors
of septic mice was 0.96 (95% CI: 0.92 - 0.98), indicating excellent inter-rater reliability. The
Cronbach alpha coefficient was 0.92, indicating excellent internal consistency of the MSS.
For a concentration of 90 mg/mL FS, we calculated a mortality rate of 42% within 1 hour
of attaining a score of 10, and a mortality of 75% within 2 hours of attaining a score of 10. Fifty66

seven percent of mice that reached a score of 15 died or had to be euthanized (as per ethics
guidelines) within 1 hour, and 86% of mice that reached a score of 15 died within 2 hours. Based
on the ROC curve generated for the MSS (Figure 7D), the AUC (95% confidence interval) was
0.825 (0.752 - 0.898) with a p value < 0.0001, suggesting that the scoring system has excellent
discriminatory power. An MSS of 3 (Youden score of 0.61) was selected as the cut-off point for
mice that progressed to severe sepsis post-FIP induction: the sensitivity (±95% C.I.) and
specificity (±95% C.I.) of this score was 57% (47-67%) and 100% (82-100%), respectively.
When organs were homogenized and plated on agar, bacterial growth was observed in all
tissues, including liver, spleen, heart, lung, and kidneys (Figure 7C). Consistent with the
polymicrobial nature of the model, significant variations in colony size (ranging from 1-3 mm in
diameter), colour (white, brown, and yellow), and CFU counts were observed. Bacterial counts
were not observed in any organs recovered from sham mice (data not shown). We did not
observe a correlation between sepsis score and CFU counts in FIP mice.
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Figure 7: Characterization of a mouse model of acute intra-abdominal sepsis (IAS).
(A) Mouse survival over time versus concentration of fecal solution (FS; n = 20 mice per
concentration of FS). (B) Murine Sepsis Score (MSS) over time of mice that were administered
90 mg/mL FS (n = 20, 1 representative experiment). (C) Viable bacterial colony forming units
(CFU) recovered from solid organs of mice treated with 90 mg/mL FS, at the time of euthanasia
(n = 5). (D) Receiver-operator curve (ROC) evaluating the sensitivity and specificity of the MSS
in differentiating healthy mice from those that progress to septic shock and death.
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On necropsy, FIP mice were observed to have developed diffuse intestinal distension
compared to uninfected control mice (Figure 8). In addition, FIP mice had peritoneal and
mesenteric lymphadenopathy, and rarely developed abscesses. We also routinely observed the
presence of a yellow fibrin film on the surfaces of the intra-abdominal organs, most notably
overlying the liver and spleen. We did not identify any grossly visible areas of necrosis or
ischemia within the organs. In mice that were euthanized due to severe respiratory distress, we
observed minor pulmonary haemorrhage and the lungs appeared edematous.
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Figure 8: Necropsy of naïve and septic B6 mice.
Macroscopic intra-abdominal view of control (left) and 90mg/mL FIP mouse (right) at 24h
reveals significant intestinal distension in the latter (size bar, 1 cm).
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Serum biochemistry demonstrated significantly elevated AST and ALT levels in the FIP
group at 6, 12, 18, and 24 hours post-sepsis induction (p < 0.001) compared to the sham group
(Figure 9A). However, both AST and ALT levels peaked at 6 to 12 hours in septic mice: while
the AST levels declined and rose again at 18 and 24 hours respectively, the ALT levels fell
sharply at 18 and 24 hours. A linear correlation between liver transaminases and MSS was only
significant for the first 12 hours of the experimental timeline, but was non-significant for the
entire duration (24 hours) of the experiment. Serum glucose and creatinine did not demonstrate
significant changes over time in the FIP group (Figure 9B, C). Serum albumin levels decreased
significantly at 3 and 12 hours post-sepsis compared to the sham group (p = 0.0057 and p =
0.018, respectively), but there was no difference in albumin levels after 24 hours (Figure 9D).
We observed a trend towards higher lipase levels at 24 hours post-sepsis but there was
significant variability in lipase activity among individual mice in the FIP group (Figure 9E).
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Figure 9: Serum biochemistry of B6 mice with IAS.
Blood serum biochemistry of (A) liver enzymes aspartate transaminase (AST) and alanine
aminotransferase (ALT), (B) Glucose, (C) Creatinine, (D) Albumin, and (E) Lipase (n = 4 in
donor group; n = 12 for sham group; n ≥ 4 per group at 3 h, 12 h, 16 h, 18 h, and 24 h). Mean
values shown with SEM error bars. * p <0.05, ** p <0.01, *** p <0.001.
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Histological examination of the tissues demonstrated different degrees of pathology in
various organs at 24 hours after FIP (Figure 10). In the lung, we observed mild edema in the
alveolar spaces and leukocyte accumulation in the peripheries of pulmonary arterioles. In the
liver of mice with FIP, parenchymal cells demonstrated vacuolization, limited necrosis, and loss
of organization and structure. We also occasionally observed capsular edema and recruitment of
inflammatory cells onto the liver surface. The spleen demonstrated significant changes postsepsis, with expansion of the white pulp, and widespread cellular apoptosis, which was also
confirmed by TUNEL staining (Figure 10). At higher concentrations of FS (180 mg/mL),
pathological changes associated with damage and inflammation could be observed within 12
hours of insult (data not shown). We also observed pathological changes in the small intestine
(Figure 10), characterized by the loss of goblet cells and loss of villi. We did not observe the
accumulation of neutrophils or other leukocytes within the submucosa, but we occasionally
observed necrosis and debris on the serosal surfaces of the gastrointestinal tract. We did not
observe pathological changes in the hearts or brains of septic mice at 24 hours (data not shown).
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Figure 10: Histology of sham-treated and septic B6 mice.
Representative tissues from sham-treated and septic mice at 24h developed with TUNEL or
haematoxylin and eosin (size bar, 50µm).
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Analysis of cytokine levels by multiplex array showed a rapid, sustained, and significant
increase of the putative markers of experimental sepsis, namely IL-1β, IL-6, IL-10, and TNF-α,
in FIP mice over a 24-hour period (p < 0.001) versus the sham group (Figure 11). Additionally,
we observed increased levels of eotaxin, M-CSF, MIG, MIP-1α, MIP-1β, MIP2, IL-5 and IL-15.
IL-5 and IL-15 returned to baseline levels by 12 hours; however, IL-5 was detected at
significantly increased levels at 24 hours, compared to the control group (p < 0.001). Results of
additional analysed cytokines, which are well described in septic models, are shown in Table 11.
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Figure 11: Serum cytokines and chemokines in septic B6 mice.
Sham and FIP (90 mg/mL) cytokine and chemokine levels (pg/mL) at 3, 12, and 24h post FIP
induction. Mean serum protein concentrations ± SEM are shown (n = 12 for sham group; n ≥ 3
for 3, 12, and 24h groups). *p <0.05, **p <0.01, ***p <0.001.

76

Table 11: Changes in concentrations of chemokines and cytokines in sham- and 90 mg/mL FStreated mice with IAS.
Cytokine /
Chemokine

Sham

P
Value

IAS
3h

12h

24h

IL-1α

81.14 ± 22.79

313.91 ± 25.18

ND

1089.33 ± 141.89

<0.001

IL-12p40

10.14 ± 4.10

66.01 ± 13.74

0.91 ± 0.91

86.76 ± 8.97

<0.001

IL-12p70

39.81 ± 24.53

48.14 ± 17.62

28.78 ± 17.15

70.83 ± 36.10

ns

IL-13

218.93 ± 31.44

413.71 ± 17.57

315.23 ± 39.11

812.51 ± 171.84

<0.001

IL-17A

5.45 ± 1.13

403.32 ± 132.46

103.32 ± 33.20

1954.34 ± 538.63

<0.001

IP-10
(CXCL10)

59.42 ± 9.45

553.66 ± 223.84

155.26 ± 51.19

1059.87 ± 98.50

<0.001

556.53 ±
121.08

30212.64 ± 109.51

28136.57 ± 2005.17

30600.09 ± 84.61

<0.001

LIF

0.95 ± 0.46

60.67 ± 16.62

31.58 ± 6.64

377.38 ± 66.71

<0.001

G-CSF
(CSF3)

1159.18 ±
289.34

39854.47 ± 224.65

39942.15 ± 207.13

39855.60 ± 335.01

<0.001

GM-CSF
(CSF2)

46.33 ± 5.53

212.57 ± 19.99

92.79 ± 19.11

349.34 ± 29.02

<0.001

MCP-1

34.51 ± 6.32

3568.44 ± 1114.53

1182.31 ± 85.60

27602.38 ± 806.52

<0.001

RANTES
(CCL5)

17.96 ± 4.15

106.74 ± 14.70

108.34 ± 19.58

1321.31 ± 147.91

<0.001

VEGF

2.67 ± 1.14

5.01 ± 0.81

13.75 ± 12.11

5.24 ± 2.19

ns

KC (CXCL1)

Mean concentrations ± SEM are given in pg/mL (n = 12 for sham mice; n = 3 in the 3h, 12h, and
24h FIP groups respectively; ns: not significant; ND: not determined).
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3.3 iNKT cells are pathogenic in intra-abdominal sepsis
Given our finding of elevated iNKT cell proportions in human sepsis/severe sepsis, and
the multiple studies that have demonstrated the pathogenicity of iNKT cells in animal models
mimicking chronic polymicrobial sepsis [159], we studied iNKT cells in our mouse model of
IAS. Since iNKT cells can rapidly produce pro- and/or anti-inflammatory cytokines in response
to stimuli and shape the subsequent immune responses in various diseases [174, 235], we
hypothesized that these cells would affect disease severity and survival in IAS. Compared to
C57BL/6 (B6) mice, we observed a significant reduction in sepsis severity (Figure 12a) and
mortality (Figure 12b) in Jα18-/- mice, which selectively lack iNKT cells [230]. Whereas an
intra-peritoneal injection of a fecal slurry solution (90 mg/mL) in B6 mice resulted in 100%
mortality at 24 hours, the sham B6 and Jα18-/- groups, which were injected with normal saline, as
well as the septic Jα18-/- group, remained alive. On necropsy, we observed discrete abscess
collections overlying the intestines and liver in septic Jα18-/- mice, whereas septic B6 mice
developed intestinal distension and edema without abscess formation (Figure 13).
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Figure 12: iNKT cells are pathogenic in intra-abdominal sepsis (IAS).
(a) B6 and iNKT-deficient Jα18-/- mice (n= 6) were injected with fecal slurry (90mg/mL) to
induce IAS and monitored during the experimental timeline. Murine sepsis scores were
significantly higher compared to sham-treated B6 and Jα18-/- mice (injected i.p. with normal
saline [NS]) and Jα18-/- mice with IAS (n= 6 for sham B6 and Jα18-/- mice each, n= 10, n= 6 for
septic B6 and Jα18-/- mice respectively). ***p< 0.001 by two-way ANOVA test. (b) Mortality
for B6 mice with IAS were significantly higher than sham B6 and Jα18-/- mice, as well as septic
Jα18-/- mice (n= 6 for sham B6 and Jα18-/- mice each, n= 10, n= 6 for septic B6 and Jα18-/- mice
respectively). ***p< 0.001 by log-rank test
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Figure 13: Necropsy of sham and septic B6 and Jα18-/- mice.
On necropsy, septic B6 mice had significant intestinal distension (white arrow) compared to
sham-treated B6 mice. The omentum (black arrow) was also enlarged in septic B6 mice. Jα18-/mice formed discrete abscesses (white arrowheads) overlying the liver and intestines, with no
intestinal distension (size bar, 0.5 cm).
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To assess whether iNKT cells were migrating to the omentum or proliferating within
their native tissues, we adoptively transferred 5×105 GFP-expressing iNKT cells from transgenic
mice into Jα18-/- mice through a tail-vein injection. After 18 hours, we induced sepsis by
intraperitoneal administration of fecal slurry (90 mg/mL) and monitored mice for 24 hours. Mice
that received iNKT cells fared worse than Jα18-/- that did not receive iNKT cells (Figure 14),
with respect to disease severity. None of the mice in either group died at the end of the
experimental timeline. Together, these results confirm the pathogenic nature of iNKT cells in
IAS.
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Figure 14: Adoptive transfer of iNKT cells into iNKT-deficient mice.
Splenic and hepatic iNKT cells were isolated and sorted from GFP-expressing transgenic mice,
and injected i.v. into Jα18-/- mice. After 18 hours, mice were administered a fecal slurry (90
mg/mL) to induce IAS and monitored for 24 hours. Adoptive transfer of iNKT cells increased
the severity of sepsis (a) compared to Jα18-/- mice that did not receive iNKT cells. (b)
Adoptively-transferred iNKT cells moved into the omentum of Jα18-/- mice following IAS, as
detected by flow cytometry, compared to adoptively-transferred iNKT cells in sham Jα18-/- mice.
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3.4 Tissue-specific distribution of iNKT cells is altered in IAS
Previous animal studies using a model of chronic polymicrobial sepsis found that the
frequency of hepatic iNKT cells declined significantly, whereas splenic iNKT cells remained
unchanged [159]. We sought to determine whether a similar occurrence would be observed in
acute IAS. Furthermore, we hypothesized that the omentum, which has been described as the
“policeman of the abdomen” for its ability to migrate to and mitigate inflammatory reactions
[229] may accommodate increased numbers of iNKT cells post-sepsis.
Using flow cytometry, we determined the frequencies of TCRβ+CD1d tetramerconventional T cells and TCRβ+CD1d tetramer+ iNKT cells in the spleen, liver and omentum. In
the spleen (Figure 15a), the percentage of conventional T cells declined significantly post-sepsis
from 44.5% to 31.2% (p= 0.0128). The percentage of splenic iNKT cells also reduced
significantly post-sepsis from 1.18% to 0.33% (p= 0.0046). In the liver (Figure 15a), there was
no difference in the tissue-specific distribution of iNKT or T cells. In the omentum (Figure 15a),
the percentage of T cells increased significantly post-sepsis from 12.78% to 38% (p= 0.0095),
and the percentage of iNKT cells were also significantly elevated post-sepsis from 0.58% to
5.5% (p= 0.040).
We also sought to quantify the transcriptional expression of the invariant TCR following
IAS, because the surface receptors of iNKT cells (including the TCR and NK1.1) can be downregulated upon activation [245, 246], and become undetectable by flow cytometry using standard
reagents [245]. Using the Taqman assay with custom designed primers that overlap the invariant
TCR Vα14-Jα18 splice site and amplify a portion of the TCR [173, 178], we observed significant
increases in the transcriptional expression of the invariant TCR within the spleen, liver, and
omentum post-sepsis (Figure 15b). Together, these results demonstrate that the tissue-specific
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distribution of iNKT cells is altered significantly during IAS, and that the transcription of the
invariant TCR is increased post-sepsis.
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Figure 15: Tissue-specific distribution of iNKT cells is altered during IAS
(a) The distribution of T and iNKT cells in the spleen and omentum is altered significantly in
IAS, but remains unchanged in the liver (n= 7, n= 10 in sham and IAS groups respectively).
Percentages of cell populations are represented as means ± SEMs. *** p<0.0001, ** p<0.001, *
p<0.05 by Mann Whitney U test (b) Quantitative RT-PCR detecting iNKT cells in the spleen,
liver, and omentum.
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3.5 Th2-polarized iNKT cells reduce disease severity in IAS
Multiple groups, including ours, have examined the use of glycolipids to modulate
cytokine responses in iNKT cells, and ameliorate disease severity in mouse models of
autoimmune diseases such as Type 1 Diabetes [204, 209] and rheumatoid arthritis [205-207].
Since the acute phase of intra-abdominal sepsis is primarily characterized by a marked proinflammatory or Th1-type response that contributes to mortality [14, 18, 56, 57, 70], we
hypothesized that administration of a Th2-polarizing glycolipid would reduce disease severity in
sepsis. OCH is an iNKT cell agonist which results in a Th2-biased cytokine profile when
administered in vivo [202, 235]. Similar to previous studies by our group and others [209, 235,
247], we demonstrated that the i.p. injection of OCH into naïve B6 mice results in a rapid peak
of serum IL-4 at 2 hours, and is then significantly reduced at 12 to 24 hours (Figure 16); in
contrast, serum levels of the Th1 cytokine IFN-γ peaked at 12 hours, but was almost
undetectable at 24 hours (Figure 16). The administration of the prototypical iNKT cell agonist
KRN7000 [186] resulted in elevated serum levels of IFN-γ between 12 and 24 hours (Figure
16). The IL-4: IFN-γ ratio calculated based on the peak values of these cytokines was higher for
OCH compared to KRN7000, confirming that OCH promotes a Th2-dominant cytokine response
in vivo.
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Figure 16: Effect of glycolipid agonists on cytokine expression in naïve B6 mice.
Naïve B6 mice were injected i.p. with 4 µg OCH, KRN7000 or C20:2, and bled at 2, 12, and 24
hours post-injection. Serum samples were assayed for IL-4 and IFN-γ by enzyme-linked
immunosorbent assay (ELISA). Each data point shows mean (± SEM) of two or three mice from
one representative experiment. Vehicle-treated mice had cytokine levels below limits of
detection.
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Treatment with OCH prolonged survival in septic mice compared to both vehicle and
KRN7000 treatments (Figure 17a). Median survival for OCH-treated mice was 28 hours
compared to 24 and 22 hours for vehicle- and KRN7000-treated mice, respectively (p< 0.0001
by log-rank test). Mice in the OCH group survived beyond 24 hours, whereas mortality for
vehicle- and KRN7000-treated mice was 100% by 24 hours. OCH-treated mice (Figure 17b)
also had a significantly lower MSS (± SEM) of 13 ± 0.53 after 24 h compared to vehicle- and
KRN7000-treated mice with IAS (20 ± 0.33 and 18 ± 0.74 respectively, p< 0.0001 by two-way
ANOVA with Bonferroni post-test). There were no statistical differences in MSS between the
vehicle and KRN7000 treatments (p= 0.8 by two-way ANOVA with Bonferroni post-test).
The reduced MSS for OCH-treated mice derived from significant improvements in
respiratory status, an important clinical predictor of mortality in sepsis [5, 16, 48, 248]. Most
vehicle- and KRN7000-treated mice developed respiratory distress (laboured breathing and
reduced respiratory rates) by 15 hours post-sepsis, unlike OCH-treated mice that continued to
have relatively normal respiratory rates even at 24 hours. OCH-treated mice were also more
responsive to auditory and touch stimuli whereas vehicle- and KRN7000- treated mice remained
non-responsive and slow-moving or stationary. In addition, we did not observe any differences in
disease severity between vehicle- and OCH-treated J18-/- mice with IAS (Figure 17c),
confirming that the beneficial effects of OCH on sepsis severity and mortality in B6 mice are
linked to the specific modulation of iNKT cells. Vehicle-treated J18-/- mice had a mean (±
SEM) MSS of 8.7 (± 0.33) whereas OCH-treated J18-/- mice had a mean (± SEM) MSS of 9.3
(± 0.33; p= 0.10 by two-way ANOVA with Bonferroni post-test).
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Figure 17: Th2-polarizing glycolipid OCH reduces disease severity in IAS.
(a) OCH-treated B6 mice had significantly prolonged survival compared to vehicle- and
KRN7000-treated mice (n= 19, n= 15, n= 8 for OCH, vehicle, and KRN7000 groups
respectively). ***p< 0.001 by log-rank test (b) OCH-treated mice demonstrated significantly
reduced disease severity compared to vehicle-treated and KRN7000-treated mice (n= 19, n= 15,
and n= 8 mice respectively for OCH, KRN7000, and vehicle groups). ***p <0.001 by two-way
ANOVA with Bonferroni post-test. (c) iNKT-deficient Jα18-/- mice were given fecal slurry (FS;
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90mg/mL) to induce intra-abdominal sepsis (IAS) and concomitantly treated with OCH or
vehicle. Murine sepsis scores were similar between vehicle and OCH-treated mice (n= 3 per
group). (d and e) Administration of OCH and KRN7000 resulted in significantly reduced
detection of iNKT cells among septic B6 mice compared to vehicle treatments. The percentages
of T cells remained unchanged with administration of iNKT-specific glycolipid agonists (n= 6,
n= 4, n= 6, and n= 3 for vehicle, OCH, Vehicle (KRN7000) and KRN7000 groups respectively).
*p <0.05, **p <0.01 by Mann-Whitney U test. (f) Bacterial counts in blood and multiple organs
were similar between vehicle-, OCH-, and KRN7000-treated mice with sepsis (n= 7-9 per
group). Data are representative of at least three independent experiments.
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Next, we analyzed the spleens and livers of septic mice treated with the glycolipid
agonists but did not detect differences in splenic or hepatic T cell distributions (Figure 17d and e
respectively). We did not determine any differences in splenic T cell distributions (Figure 17d)
when septic mice were treated with OCH (29.7%), vehicle (35.0%), or KRN7000 (33.2%; p=
0.42). Hepatic T cell distribution was also unchanged between OCH (55.9%), vehicle (56.8%)
and KRN7000 treatments (58.2%, p= 0.44) (Figure 17e). However, we had significantly reduced
detection of iNKT cells in the spleen and liver following glycolipid treatment (Figure 17d and
e). Splenic iNKT cells reduced from 1.2% in vehicle-treated mice to 0.30% in OCH-treated mice
(p= 0.010) and 0.04% in KRN7000-treated mice (p= 0.0090). Hepatic iNKT cells reduced from
1.3% in vehicle-treated mice to 0.44% in OCH-treated mice (p= 0.0021) and 0.22% in
KRN7000-treated mice (p= 0.0003). This likely reflects the down-regulation of the surface TCR
that occurs with administration of glycolipid agonists, as shown previously by our group and
others [[207, 235, 247, 249]; Figure 17e). In particular, we observed a significantly lower
detection of iNKT cells following KRN7000 treatment compared to treatment with OCH. The
differential degree to which the glycolipids down-regulate the surface TCR is a reflection of their
differential binding kinetics to iNKT cells. While OCH and KRN7000 down-regulate the surface
TCR within 4-12 hours post administration, KRN7000 is approximately 10-fold more potent at
down-regulating the TCR after 24 hours [249], leading to the results we observed in Figure 17.
Anti-inflammatory processes are concomitantly initiated to mitigate pro-inflammatory
states in sepsis, both systemically [58-61], and in individual organs [64]. These
immunosuppressive mechanisms decrease the responsiveness of cells of the innate and adaptive
immune systems, thereby increasing susceptibility to opportunistic and additional infections [6568]. Importantly, we observed that the use of OCH, which significantly reduced the production
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of the pro-inflammatory cytokine IFN-γ [207, 209, 235], did not worsen the microbial load of
septic mice, compared to vehicle and KRN7000 treatments (Figure 17f). Therefore,
administration of the Th2-polarizing glycolipid OCH did not result in overt susceptibility to
microbial infection. Additionally, OCH-treated mice that survived to 48 hours demonstrated a
significantly lower bacterial count in all tested organs, compared to OCH-treated mice that died
at 24 hours (data not shown). Sham mice, as expected, did not demonstrate bacterial organ
counts (data not shown).
Lastly, we tested the effect of a second Th2-polarizing glycolipid C20:2 on disease
severity in IAS, to confirm whether the Th2-biased modulation of iNKT cells was responsible
for ameliorating disease severity. C20:2 is a potent agonist with a capacity to bind and activate
iNKT cells that is significantly stronger than OCH [209, 235]; administration of C20:2 in naïve
B6 mice also results in a more pronounced Th2 response at 24 hours than OCH [209, 235]
(Figure 18). When septic B6 mice were treated with C20:2, we observed a significant reduction
in MSS between 20 and 24 hours compared to vehicle-treated mice (Figure 18), with improved
respiratory status at observed time points. These results confirm the novelty of manipulating
iNKT cells into a Th2-biased state for the mitigation of disease severity in IAS. However, the
MSS continued to rise in C20:2-treated mice, in contrast to OCH, where the MSS reached a
plateau (Figure 17b). Based on these results, we elected to focus on OCH and the means by
which it improves mortality in IAS.
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Figure 18: Murine Sepsis Scores for septic B6 mice treated with C20:2.
Mice were injected with fecal slurry and C20:2 or vehicle solution and monitored for 24 hours
(n= 5, n= 15 mice for C20:2 and vehicle groups respectively). ***p<0.001 by two-way ANOVA
test.
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3.6 The pro-inflammatory cytokine profile in IAS is ameliorated by
administration of OCH
In order to further understand the impact of the glycolipid agonists on the septic response,
we assessed the concentrations of 32 cytokines and chemokines from the sera and spleens of
vehicle-, OCH-, and KRN7000-treated septic mice, as well as sham treated mice (Figure 19a-c,
Table 12, and Table 13). In the serum, mean concentrations of IL-17 was significantly lower in
the OCH-treated mice compared to KRN7000-treated mice (p= 0.041 by one way ANOVA with
post-hoc Tukey’s multiple comparison test). The concentration of IL-13 was higher in the sera of
OCH-treated mice compared to KRN7000-treated mice (p= 0.0403 by one way ANOVA with
post-hoc Tukey’s multiple comparison test). In the spleen, IFN-γ, IL-3, IL-4, IL-17, and TNF-α
were significantly elevated in the KRN7000-treated group compared to the OCH-treated group.
Therefore, the administration of OCH significantly reduces the levels of pro-inflammatory
cytokines in IAS.
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Figure 19: Cytokine levels in the sera and spleens of septic B6 mice.
(a) Sera and spleen homogenates from vehicle-, OCH-, and KRN7000-treated B6 mice with
intra-abdominal sepsis (IAS) were analyzed at 24 hours for 32 inflammatory cytokines by
multiplex array, and displayed as a heat map (n= 4 mice per group). Concentrations of iNKT
cell-specific cytokines are shown from sera (b) and spleen homogenates (c) of septic mice treated
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with vehicle, OCH, or KRN7000 (n= 4-8 per group). Concentrations of cytokines are shown in
pg/mL. *p <0.05, **p <0.01, ***p <0.001 by one-way ANOVA with post-hoc Tukey’s multiple
comparison test. Data are representative of at least three independent experiments.
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Table 12: Mean serum chemokines and cytokine concentrations (± SD) in B6 mice treated with
vehicle, OCH, or KRN7000.

Cytokine /
Chemokine

Sham
IAS

P Value

(n = 4)
Vehicle

OCH

KRN7000

(n = 4)

(n = 8)

(n = 6)

Eotaxin

302.2 ± 223.2

7735 ± 6174

5411 ± 3145

6841 ± 4311

0.6538

G-CSF

283.4 ± 47.1

40342 ± 72

40868 ± 877.5

41081 ± 989.8

0.3992

GM-CSF

48.8 ± 15.7

495 ± 169

343.6 ± 268.1

311.8 ± 221.7

0.4723

IFN-γ

8.4 ± 14.5

311 ± 392

91.93 ± 110.5

98.85 ± 77.52

0.1852

IL-1a

179.1 ± 179.2

1070 ± 524

1737 ± 958.7

1345 ± 241.6

0.3030

IL-1b

12.3 ± 12.6

234 ± 141

671.6 ± 897.4

662.4 ± 1019

0.6749

IL-2

140.4 ± 172.8

40 ± 34

94.43 ± 178.2

239.7 ± 487.5

0.5581

IL-3

-

13 ± 9.5

14.70 ± 11.33

25.55 ± 22.56

0.3637

IL-4

0.16 ± 0.28

2 ± 1.4

3.363 ± 2.944

4.197 ± 3.656

0.5371

IL-5

2.57 ± 1.97

483.0 ± 320.8

455.5 ± 331.2

455.0 ± 167.2

0.9853

IL-6

21.4 ± 0.25

26529 ± 792.8

28164 ± 1356

27887 ± 1658

0.1765

IL-7

-

6.243 ± 10.07

3.533 ± 3.946

2.275 ± 2.917

0.5461

IL-9

178.3 ± 202.6

479.9 ± 334.5

165.3 ± 130.2

243.7 ± 259.9

0.1134

IL-10

-

22733 ± 11469

11187 ± 9980

15875 ± 9750

0.2135

IL-12 (p40)

-

3731 ± 7247

100.5 ± 44.28

107.3 ± 60.38

0.4602

IL-12 (p70)

16.0 ± 3.9

24.68 ± 10.31

104.2 ± 88.68

161.6 ± 218.7

0.3824

IL-13

270.6 ± 273.0

636.1 ± 165.2

1246 ± 626.3

775.1 ± 275.1

0.0403

IL-15

155.6 ± 174.8

321.1 ± 203.0

215.5 ± 139.1

447.1 ± 205.7

0.0775

IL-17

1.58 ± 2.42

3893 ± 2716

3301 ± 3184

7578 ± 3822

0.1858

IP-10

52.4 ± 41.3

28253 ± 43784

3332 ± 4097

4227 ± 2912

0.2907

KC

389.7 ± 369.3

29810 ± 1057

28626 ± 2871

27521 ± 3275

0.1489

LIF

-

289.0 ± 196.6

275.0 ± 137.2

343.4 ± 149.8

0.4501
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LIX

2261 ± 3298

1848 ± 329.6

4842 ± 3144

2868 ± 518.2

0.1108

MCP-1

28.76 ± 32.32

23343 ± 14846

21132 ± 10003

24296 ± 8448

0.7748

M-CSF

3.93 ± 0.70

203.9 ± 48.19

1667 ± 1461

812.4 ± 828.1

0.1115

MIG

15.4 ± 10.1

8189 ± 3622

6101 ± 4333

4268 ± 4484

0.3813

MIP-1a

163.6 ± 108.3

5312 ± 3389

5456 ± 6949

6918 ± 6845

0.7355

MIP-1b

88.96 ± 120.2

18193 ± 12436

9737 ± 8622

9510 ± 8843

0.7290

MIP-2

14.8 ± 6.3

21982 ± 10040

22283 ± 5986

21423 ± 3911

0.9759

RANTES

16.1 ± 18.7

1993 ± 1201

2838 ± 3051

1870 ± 1304

0.7007

TNF-a

0±0

296.2 ± 151.8

314.4 ± 182.1

323.3 ± 155.3

0.9688

VEGF

3.7 ± 3.7

37.10 ± 54.55

24.45 ± 46.15

13.70 ± 19.06

0.9220

All concentrations are in pg/mL. Comparison was made by one-way ANOVA with post-hoc
Tukey’s multiple comparison test. P values are shown for comparison tests between OCH- and
KRN7000-treated mice.
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Table 13: Mean concentrations of chemokines and cytokines in spleen homogenates (± SD) of
septic mice treated with vehicle, OCH, or KRN7000.
Vehicle

OCH

KRN7000

P Value

(n = 1)

(n = 7)

(n = 6)

(OCH v. KRN7000)

Eotaxin

167.17

654.3 ± 503.6

1560 ± 268.2

0.0023

G-CSF

10794.18

9244 ± 6763

7813 ± 2679

0.5338

GM-CSF

11.35

10.49 ± 13.94

18.68 ± 23.47

0.5867

Ifn-γ

22.49

17.91 ± 12.77

281.7 ± 394.8

0.0221

IL-1α

3007.60

561.5 ± 318.2

562.2 ± 234.7

0.9372

IL-1β

417.44

54.16 ± 25.40

63.01 ± 12.34

0.4452

IL-2

6.31

18.05 ± 10.46

17.27 ± 8.107

0.7308

IL-3

7.03

0.8543 ± 0.9072

5.222 ± 7.079

0.0264

IL-4

0.49

3.127 ± 1.943

15.12 ± 14.78

0.0256

IL-5

0.44

4.594 ± 4.254

4.938 ± 1.595

0.4452

IL-6

87.59

2396 ± 1794

2962 ± 2484

0.6282

IL-7

5.22

6.637 ± 3.395

6.862 ± 1.686

0.5338

IL-9

28.04

61.75 ± 26.23

76.06 ± 16.90

0.4452

IL-10

40.05

58.01 ± 59.15

37.45 ± 13.97

0.9452

IL-12 (p40)

268.12

12.29 ± 11.93

22.36 ± 17.07

0.7092

IL-12 (p70)

12.22

3.837 ± 3.359

4.762 ± 2.433

0.0003

IL-13

8.28

0.3000 ± 0.6708

4.053 ± 5.847

0.2448

IL-15

31.90

19.22 ± 19.61

24.94 ± 14.15

0.5477

IL-17

2.19

14.80 ± 18.33

42.80 ± 34.79

0.0367

IP-10

3.05

483.9 ± 439.2

2507 ± 756.3

0.0088

KC

79.33

2591 ± 2041

4814 ± 2651

0.0035

LIF

108.17

15.71 ± 13.44

22.30 ± 5.966

0.5477

LIX

533.31

107.9 ± 112.7

123.1 ± 166.4

0.2163

MCP-1

1251.65

781.4 ± 702.4

1234 ± 166.7

0.0053

M-CSF

210.76

42.50 ± 32.72

45.35 ± 20.29

0.9452

Cytokine / Chemokine
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MIG

17.77

1870 ± 2010

7776 ± 7656

0.0596

MIP-1α

140.71

318.1 ± 216.2

462.9 ± 143.5

0.0167

MIP-1β

23.01

410.0 ± 282.5

698.6 ± 138.1

0.0026

MIP-2

5915.82

4937 ± 3253

6480 ± 3191

0.0134

RANTES

40.36

267.1 ± 225.6

316.2 ± 143.5

0.6991

TNF-α

4.37

7.239 ± 5.841

12.10 ± 3.006

0.1979

VEGF

3.16

7.460 ± 1.522

5.652 ± 1.646

0.0049

All concentrations are in pg/mL. Comparison was made between OCH and KRN7000-treated
mice by unpaired two-tailed t test.
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3.7 Treatment with OCH significantly reduces splenocyte apoptosis in IAS
We next sought to elucidate the reason for the improved survival among septic mice that
were treated with OCH. When we performed histopathological analysis on the spleen, liver, and
omentum of septic B6 mice treated with KRN7000 or OCH (Figure 20), we found a significant
reduction of apoptotic cells within the spleens of OCH-treated mice compared to vehicle- and
KRN7000-treated mice. The presence of karyorrhexic nuclei within clusters of cells with
eosinophilic cytoplasm was observed in the white pulp of the spleen by hematoxylin and eosin
staining, and subsequently confirmed as apoptotic cells by TUNEL staining, particularly in
vehicle- and KRN7000-treated mice (Figure 20). Based on histopathological scoring by a
pathologist blinded to the treatment, OCH-treated mice had mild apoptosis, whereas vehicletreated and KRN7000-treated mice had moderate and severe apoptosis respectively (Figure 21).
In the omentum of vehicle- and KRN7000-treated mice, we noted a significant increase
in lymphocytes whereas fewer lymphocytes were observed in the omentum of OCH-treated mice
(Figure 20). We did not observe overt differences in liver histopathology among vehicle-, OCH-,
and KRN-treated mice. When we examined the histology of C20:2-treated septic mice, we
observed a decrease in apoptosis compared to KRN7000-treated mice (Figure 22). However, the
degree of apoptosis in C20:2-treated mice was higher than OCH-treated mice with IAS.
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Figure 20: Histopathology of septic B6 mice treated with glycolipid agonists of iNKT cells.
Treatment with OCH significantly reduced apoptosis within the spleen compared to vehicle- and
KRN7000-treated mice with intra-abdominal sepsis (IAS), both by hematoxylin and eosin
staining, as well as TUNEL staining. Lymphocyte migration to the omentum is also partially
ameliorated in OCH-treated mice compared to vehicle- and KRN7000-treated mice. There were
no histopathological differences in the liver. Images are representative of 4 animals per treatment
group (n= 4 slides per animal; size bar, 50 µm).
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Figure 21: Histopathological scoring of splenic apoptosis in B6 mice with IAS.
Histopathological scoring of the degree of apoptosis observed within the spleens of sham and
septic B6 mice treated with vehicle, KRN7000, or OCH (n= 4 animals per treatment group; n= 4
slides per animal). Apoptosis was defined histologically by the presence of cell clusters with
nuclear shrinkage (karyorrhexis), dark eosinophilic cytoplasm, intact plasma membrane, and
relative paucity of surrounding inflammatory cells within the splenic follicles on H&E staining.
Scores assigned to each animal by a blinded independent pathologist were as follows: 0 for
complete absence of apoptosis; 1 for mild presence of apoptosis (0-15% per follicle); 2 for
moderate apoptosis (16-30% per follicle); and 3 for severe apoptosis (31-45% per follicle). ***
p< 0.0001 by two-tailed Mann Whitney U test.
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Figure 22: Histopathology of C20:2-treated B6 mice with IAS.
C57BL/6 (B6 mice) were injected intraperitoneally with 500 µL of FS (90 mg/mL) to induce
IAS, and concomitantly injected with 4 µg of the glycolipid C20:2. Mice were sacrificed at 24
hours, and the liver, spleen, and omentum were removed and processed for histopathological
analysis. These images are representative of 5 septic B6 mice that were treated with C20:2 (size
bar, 25 µm).
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We then performed flow cytometry on spleens harvested from vehicle-, OCH- and
KRN7000-treated mice with IAS to determine the immune cell populations that had undergone
apoptosis (Figure 23). Treatment with OCH significantly reduced the apoptosis of T and B cells
compared to vehicle- and KRN7000-treated mice. However, there were no differences in the
frequency of apoptotic macrophages between the KRN7000 and OCH groups, although both
treatments reduced the frequency of apoptosis significantly compared to vehicle-treated mice.
With respect to NK cell apoptosis, we observed a trend toward reduced apoptosis in KRN7000treated mice. Together, these results demonstrate that different glycolipid agonists of iNKT cells
differentially mitigate the apoptosis of splenic lymphocytes, but not NK cells and macrophages.
Moreover, Th2-polarizing glycolipids significantly reduce lymphocyte apoptosis within the
spleen, a critical predictor of mortality in severe sepsis and septic shock [71, 84, 134].
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Figure 23: Analysis of apoptotic cell populations in the spleens of septic B6 mice.
(a) Splenocytes from sham and septic B6 mice treated with OCH, KRN7000, or vehicle were
stained for T, B, and Natural Killer (NK) cells, and macrophages, and further stained for
Annexin V (a marker for early apoptosis) and 7-AAD viability dye. (b) Early and late apoptotic
cells (Annexin V+ 7AAD- and Annexin V+ 7AAD+ cells, respectively) were quantified and
compared between treatments. OCH treatment significantly reduced apoptosis among T and B
cells, as well as macrophages, but not NK cells (n= 3-6 mice per group). *p <0.05, **p <0.01,
***p <0.001 by one-way ANOVA with post-hoc Tukey’s multiple comparison test. Data are
representative of 3 independent experiments.
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Chapter 4: Discussion
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4.1 Discussion
iNKT cells exert profound and diverse regulatory functions in health and disease,
bridging the innate and adaptive defense mechanisms in a variety of immune responses [141,
155, 172]. Here, we demonstrate that patients with sepsis/severe sepsis have significantly
elevated proportions of iNKT cells and that OCH, a Th2-polarizing glycolipid agonist of iNKT
cells, profoundly reduces disease severity in IAS, with significantly reduced lymphocyte
apoptosis within the spleen. These findings introduce iNKT cells as potential therapeutic targets
for the treatment of sepsis.
In this thesis, we elected to utilize the fecal-induced peritonitis (FIP) model to simulate
IAS in a reproducible and reliable fashion, and to mimic the clinical presentation and prognosis
of acutely ill patients with IAS. Animal models that can reliably replicate the clinical
characteristics of sepsis are essential for the study of this disease and for the development of
novel diagnostic biomarkers [250], and new therapeutic strategies [3, 10, 18, 250-252]. The
failure of therapies that showed promise during the preclinical stages, but yielded little benefit in
human trials [251, 253], have highlighted the shortcomings of conventional animal models of
sepsis [251, 252, 254]. The cecal ligation and puncture (CLP) model, often considered the “gold
standard” among polymicrobial sepsis models [161, 232, 251, 253, 255], establishes a mixed
bacterial infection with an inflammatory source of necrotic intestinal tissue [255-257]. It
involves the performance of a laparotomy, ligation of the cecum in a non-obstructing manner,
and puncture of the ligated portion to allow fecal content to leak into the normally sterile
peritoneal cavity [161]. Despite its widespread use, however, the CLP model and its
modifications, such as cecal ligation and incision (CLI) and colon ascendens stent peritonitis
(CASP), is acutely dependent on operator technique [232, 251, 258, 259]: the percentage of
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cecum that is ligated (and thus the amount of necrosis that is induced), the amount of the
microbial dose that enters the peritoneum (which depends on the number and size of punctures
and the pressure exerted on the cecum), the size of the incisions made in the skin and abdominal
muscle, and even the use of different anaesthetic agents can considerably alter the outcome after
CLP, precluding comparison between studies [161, 251, 255, 256]. Moreover, the CLP model
more closely resembles intra-abdominal abscess formation [255, 257], which represents a
different host response [255, 257] compared to our model.
The FIP model is also advantageous to use because the protocol can be easily modified to
alter disease severity and outcome, by simply varying the concentration of feces in solution. A
further striking advantage is that the preparation of the fecal solution and the injection can be
highly standardized; therefore, our protocol provides a controlled setting that minimizes the
number of variables influencing outcome, and resolves the inter-operator inconsistency
associated with the CLP, CLI, and CASP models. In addition, an identical microbial load and
composition is given to each mouse, avoiding the potential inconsistency of each individual
mouse’s microbiota leaking from the ligated cecum. The need for anesthesia is also obviated
with the FIP model, removing another confounding factor that has been shown to alter innate
immunity in animal models such as CLP [260, 261].
We consistently demonstrated bacterial growth in every major organ in septic mice, with
similar tissue CFUs in independently performed experiments. While this study was limited by
the inability to culture and identify strictly anaerobic microorganisms, we observed colonies that
varied in size, shape, and color, confirming the polymicrobial nature of the infection.
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In this study, we also developed a robust and comprehensive scoring system with high
specificity and sensitivity in predicting severe sepsis and mortality during the experimental
timeline. Our scoring system reliably predicts 1-hour and 2-hour mortality when clinical scores
are greater than 10, with excellent discriminatory capacity. To our knowledge, the development
of a sepsis score that can reliably predict acute mortality is novel among studies using animal
models of acute sepsis and septic shock. Mice that attained a clinical score of 3 had 100%
specificity for dying from sepsis during the experimental timeline. Although the murine sepsis
score was developed in conjunction with our model, it may also potentially be used for other
models of sepsis, including CLP.
Histologically, we observed changes at the organ level that were inconsistently reported
in the CLP model, likely because of surgical variability in the latter technique. In the lung, we
did not observe extravasation of red cells and accumulation of inflammatory cells into the air
spaces as described by Zingarelli et al [262]. Doi et al did not observe any histological changes
in other organs with CLP [263], although they noted that CLP caused renal tubular damage
mainly consisting of tubular vacuolization [264, 265]. Surprisingly, while we observed gross
intestinal distension in FIP treated mice where the intestinal tract manifested subtle
histopathological changes that have been described in other sepsis models, including the loss of
glandular structure and intestinal epithelial villi, edema of the lamina propria, capillary
hemorrhage, ulceration and apoptosis [266, 267]. Apoptosis was most evident in the spleen, as
confirmed by TUNEL staining. As we demonstrated in later experiments during this thesis, T
and B lymphocytes, NK cells, and macrophages all underwent apoptosis, corroborating similar
results shown in the CLP model by Hotchkiss et al [70, 71]. These results corroborate human
studies that indicate that apoptotic factors modulate lymphocyte and monocyte activity [71, 268],
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with significant implications for immunosuppression and mortality in sepsis. The biochemistry
data consistently suggests hepatic and possibly pancreatic dysfunction may be contributing to
mortality, while the overwhelming cytokine dysfunction may also play a significant role, as
suggested by other studies [268].
The putative cytokine markers of sepsis, including IL-1β, IL-6, IL-10 and TNF-α [18,
269], increased significantly during the experimental timeline. For what we believe is the first
time, however, we also demonstrate that levels of eotaxin, IL-5, IL-15, M-CSF, MIG, MIP-1α,
MIP-1β, and MIP-2 rise significantly during sepsis. Eotaxin and IL-5 are associated with
eosinophil recruitment and function [270], although eotaxin inhibits neutrophil recruitment
during the acute inflammatory phase of sepsis [271]. IL-15, M-CSF, MIG, MIP-1α, MIP-1β and
MIP-2 promote cellular differentiation, activity, survival, recruitment and chemotaxis [272-274],
confirming the complexity of the dysregulated immune response during sepsis.
Corroborating other studies that demonstrate pathogenicity of iNKT cells in sepsis [156,
157, 159], iNKT-deficient Jα18-/- mice were resistant to IAS in this study. We also show that the
tissue-specific distribution of iNKT cells is altered during IAS, with significant reductions in the
spleen, and a concomitant rise in the omentum. The human omentum has been described as the
“policeman of the abdomen” for its ability to adhere to sites of intra-abdominal pathology and
prevent widespread pathogen contamination [219, 225]. Similarly, the murine omentum has been
shown to facilitate the regeneration of damaged tissues [229]. These results, as well as the
findings of Lynch et al, who demonstrated that the human omentum contained a rich reservoir of
iNKT cells [185], prompted us to examine the murine omentum, wherein we observed a
significant increase in iNKT cells post-sepsis. Our observation that the omentum became
enlarged during IAS correlates with findings by Shah et al [229], and represents a unique feature
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of this organ that has not been noted in other secondary lymphoid structures such as lymph nodes
or spleens. T cells were also noted to be significantly increased in the omentum during IAS,
corroborating observations made by Carlow et al [215] in a cecal ligation and puncture (CLP)
model of polymicrobial sepsis. This was also confirmed by adoptive transfer experiments: iNKT
cells that were transferred intravenously into iNKT-deficient mice moved into the omentum
during IAS. While Barral and associates demonstrated that iNKT cells exit the spleen and enter
the bloodstream in response to infection [275], the omentum may serve as a potential conduit for
iNKT cells to help facilitate intra-abdominal immune response during IAS. Although it was
beyond the scope of this study, we are currently investigating the frequency, function, and
phenotype of omental iNKT cells in human sepsis to determine their role in regulating disease
severity, and evaluate their prognostic significance.
Our results with respect to the tissue-specific distribution of iNKT cells post-sepsis
contrast the findings of Hu et al [159], who demonstrated a significant reduction in hepatic iNKT
cells but no changes in the frequency of splenic iNKT cells, in the CLP model. We propose that
splenic iNKT cells mobilize more readily during acute sepsis compared to hepatic iNKT cells,
since a recent study by Barral et al [275] showed that splenic iNKT cells patrol the red pulp and
marginal zones of the spleen, rapidly sample blood-borne antigens, and display migratory
capabilities. This may explain our observed changes in splenic iNKT cell frequency post-sepsis,
and additionally suggests that the iNKT cells we detected in the omentum post-sepsis may have
originated from the spleen, given that the two organs are physically attached to each other [229].
Glycolipid ligands of iNKT cells have been used successfully in experimental models of
autoimmune diseases [203-205, 207, 212] and solid-organ transplantation [208], as well as in
clinical trials of viral infections and various types of cancer [189, 190]. KRN7000 [186] reduces
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morbidity and mortality associated with murine graft-versus-host disease [198, 199], while OCH
mitigated disease severity in non-obese diabetic mice [204], experimental autoimmune
encephalomyelitis [202], and collagen-induced arthritis [205, 206]. OCH also prevented disease
symptoms in a humanized mouse model of citrullinated fibrinogen-induced inflammatory
arthritis [207], and delayed Th1-mediated cardiac allograft rejection in mice [208].
In our study, we show that the administration of OCH ameliorated the severe proinflammatory Th1-type response associated with IAS and reduced mortality. Although proinflammatory cytokines such as IFN-γ and TNF-α contribute to immune responses against
bacterial infections [276], elevated levels of these cytokines are also associated with poor
outcomes and decreased survival in sepsis [[277, 278];(Shrum et al, submitted)]. As confirmed in
this study, the treatment of septic mice with KRN7000 resulted in a Th1-type response at 24
hours [141, 235, 279] and did not affect disease severity. In addition, elevated levels of the Th2
cytokine, IL-13, may be contributing to the significant improvements in respiratory status and
disease severity that we observed in OCH-treated mice. A potent anti-inflammatory cytokine
[280, 281], IL-13 is produced in large quantities by alveolar macrophages in the lung during
polymicrobial sepsis [280], and has been shown to protect mice from endotoxic shock when
administered in vivo [282]. Since a compromised respiratory status significantly increases
morbidity and mortality in sepsis [16, 48, 248], the selective Th2-biased modulation of iNKT
cells may provide a novel strategy to prevent this complication in the first place.
Using serum ELISA from healthy B6 mice that were administered OCH at various time
points, we demonstrated that the ratio of IL-4 to IFN-γ was significantly elevated compared to
naïve B6 mice (Figure 14) with OCH administration. We also showed that in both naïve (Figure
14) and septic B6 mice (Figure 14) that received OCH or KRN7000, we could not detect iNKT
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cells in the liver or spleen by flow cytometry. These results also confirm the activity of
KRN7000 and OCH as previously described [283]: the TCR of iNKT cells is downregulated
when activated by KRN7000, thereby reducing the detection of iNKT cells by surface antigen
staining [235, 283]. The reduced detection of hepatic and splenic iNKT cells in OCH-treated
mice also confirms its pharmacokinetic action, down-regulating surface TCR within 4 to 12
hours of glycolipid administration as previously reported [249]. Although treatment with
KRN7000 resulted in potent down-regulation of iNKT-cell TCR, as observed in other studies
[198, 235, 283], there was no effect on sepsis severity in our study. A synthetic analogue of αGalCer that has been used in most experimental studies [283], KRN7000 is a high-affinity ligand
that induces the release of Th1- and Th2-type cytokines simultaneously [140, 141], although a
single injection of KRN7000 leads to a Th1-type response after 24 hours [140, 141].
Following the initial hyperinflammatory response of sepsis is a prolonged
immunosuppressive phase that may lead to secondary infections [65-68]. Although proinflammatory cytokines such as IFN-γ and TNF-α are associated with increased morbidity and
mortality in sepsis [277, 284-286], they also contribute to immune responses against bacterial
infections [276, 287]; IFN-γ, in particular, has been shown to reverse the altered immune status
of monocytes in human sepsis [129]. Thus, one concern with Th2-polarizing agonists of iNKT
cells is that this may further dysregulate protective immunity, leading to the potential uninhibited
growth of bacterial pathogens. However, we did not observe an increase in microbial load within
the blood and organs of OCH-treated mice compared to vehicle-treated mice with IAS. Since
OCH is a less potent agonist than KRN7000, with lower binding affinity for the invariant TCR
compared to the latter [235, 249], the administration of a single dose of OCH may have affected
only a portion of iNKT cells, thereby abrogating rather than eliminating the pro-inflammatory
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response. In addition, other immune cells which are not directly affected by glycolipid
administration may continue to participate in bacterial clearance, including NK cells, which also
produce significant amounts of IFN-γ [276]. Any differences in microbial counts between
KRN7000- and vehicle-treated mice may have been masked by the excessive pro-inflammatory
response that is inherent in our sepsis model (Shrum et al, submitted). Lastly, our study also
confirms that the manipulation of iNKT cells alone can dramatically alter outcomes in sepsis,
given that iNKT-deficient mice are resistant to mortality from sepsis, and disease severity was
unaffected by glycolipid treatment in these animals.
Interestingly, the use of C20:2, another Th2-polarizing glycolipid that is significantly
more potent at inducing a Th2 bias compared to OCH [165, 209, 288] and supresses downstream
NK cell function [235], also mitigated sepsis severity significantly and reduced splenocyte
apoptosis. Unlike OCH, however, mice treated with C20:2 continued to worsen, although their
MSS remained lower than vehicle-treated mice at most observed time-points, suggesting that
while the Th2-biased manipulation of iNKT cells may be a viable therapeutic strategy in sepsis,
the use of a drug that is too potent may have unintended immunosuppressive consequences [84]:
balancing the pro-inflammatory response with OCH may therefore be better at improving
survival in IAS, rather than suppressing it with C20:2.
For what we believe is the first time, we demonstrate that Th2-polarized iNKT cells
significantly reduce apoptosis within the spleen, particularly among T and B lymphocytes, and
macrophages. Apoptosis contributes to immunosuppression during sepsis through the deletion of
critical effector cells including T and B cells, and the induction of anergy in surviving immune
cells. The loss of T and B cells significantly impairs the adaptive immune response, and, by
disabling the cross-talk between the adaptive and innate immune systems, also impairs the latter
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[17, 64, 74]. Hotchkiss et al observed a striking apoptosis-induced loss of cells of the innate and
adaptive immune systems in the spleen during sepsis, including CD4+ and CD8+ T cells, B cells,
and dendritic cells [70, 71]. The marked increase in apoptosis among circulating lymphocytes
[77] is also believed to contribute to the profound and persistent lymphopenia that is strongly
associated with mortality during sepsis.
The uptake of apoptotic cells also stimulates immune tolerance by inducing the release of
anti-inflammatory cytokines, including IL-10 and transforming growth factor-β (TGF-β), and
suppressing the release of pro-inflammatory cytokines [87]. This potential link between the
release of IL-10 by apoptotic cells and immune suppression in sepsis is underscored by studies
showing that the circulating concentration of IL-10 is predictive of a fatal outcome in patients
with sepsis [58, 88]. In the sera of OCH-treated mice, the levels of IL-10 appear to be lower than
vehicle- and KRN7000-treated mice, although splenic levels of IL-10 are higher in OCH-treated
mice compared to KRN7000-treated mice. Additionally, the uptake of apoptotic cells by
macrophages and DCs does not induce the expression of co-stimulatory molecules: therefore, T
cells that come into contact with APCs that have ingested apoptotic cells might either become
anergic or undergo apoptosis themselves [87]. Therefore, the significant reduction in splenic
apoptosis may prevent T cell anergy in OCH-treated mice. Interestingly, apoptosis of NK cells
appeared to be reduced by treatment with OCH and KRN7000, although the trend is more
pronounced for the latter. Since NK cells also produce significant amounts of IFN-γ [276], their
apoptosis in the spleens of vehicle- and OCH-treated mice may explain the reduced levels of
splenic IFN-γ in these two groups.
Interleukin-17 is significantly lower in the sera and spleen of OCH-treated mice
compared to KRN7000- and vehicle-treated mice. This cytokine has been strongly implicated in
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promoting mortality during sepsis, both in animal and human studies, by causing the Th17
response. Moreover, it has been shown that blockade of apoptosis impairs the release of IL-17
and the subsequent Th17 response in a Citrobacter rodentium infectious colitis model [289].
Indeed, blockade of IL-17 has been shown to improve mortality in several animal models of
sepsis [290, 291]. IL-17 is also involved in the apoptosis of PMNs [292] and also mediates
cardiomyocyte apoptosis [293]. Therefore, reduction of IL-17A levels may have significant
implications in improving cardiovascular output during septic shock, although it was beyond the
scope of our current study to assess this. Nevertheless, the evidence from our study therefore
suggests an alternative method to reduce mortality by manipulation of regulatory T cells without
using end-target effector drugs.
We have also demonstrated that the proportion of circulating iNKT cells is elevated early
in the septic process for critically-ill patients, corroborating a recently published study by
Heffernan et al [294]. Given their propensity to rapidly produce significant quantities of proand/or anti-inflammatory cytokines, the increased proportion of iNKT cells suggests that they
may be playing a prominent role in promulgating the immune response in septic patients.
Furthermore, we observed that the proportion of iNKT cells is not increased in patients who have
sustained significant inflammatory responses due to trauma, suggesting that these cells may be
specifically responding to microbial pathogens in humans. Consequently, the detection of
increased numbers of iNKT cells may also serve as an important biomarker to differentiate septic
from non-septic patients early in the disease process, thereby facilitating rapid and targeted
interventions for the disease.
There are several limitations to this study. We did not assess the impact of iNKT cell
modulation on the function or activity of other immune cells within the spleen or liver. Since
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iNKT cells play an important regulatory role in the context of immune responses and may be a
potential target for therapy in sepsis, an evaluation of their downstream effects on immune cells
will be necessary. One particular aspect of immune cell function in the context of Th2
modulation is that of anergy. A significant proportion of septic patients die from additional
nosocomial infections post-admission, and immunosuppression secondary to T cell anergy has
been proposed as a primary reason for this occurrence. The risk of dying after a septic episode
rises significantly within the first year, and the risk of dying after surviving an episode of severe
sepsis is significantly elevated for the next five years. A study by Perl et al [6] found that only
40% of severe sepsis patients were alive after 4 years, while only 20% of severely septic patients
were alive within 8 years after leaving the hospital. Additionally, a study by Benjamim and
colleagues showed that mice treated successfully following CLP died from reinfection when they
were exposed to pulmonary Aspergillosis several weeks later [295]. Therefore, sepsis is not only
an acute disease with acute clinical consequences, but also a syndrome that can cause chronic
medical problems. Consequently, proliferation and activation assays of OCH- and KRN7000treated mice will be necessary to determine whether the lymphocytes can still mount an effective
immune response.

4.2 Conclusion
Given the failure of many immunotherapeutic drugs in the treatment of sepsis [89, 90],
alternative agents have been sought to combat this disease with some success [106-112]. Our
results indicate that Th2-polarized iNKT cells reduce disease severity in IAS by mitigating
lymphocyte and macrophage apoptosis within the spleen, likely through reduction of IL-17.
Moreover, circulating iNKT cells are increased in critically-ill patients with sepsis compared to
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non-septic patients, and therefore they may be a potent therapeutic target in the treatment of
sepsis.
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Students and Residents Supervised for Research:
2013-2014

Januvi Jegatheswaran (BSc, MD Candidate): Assessment of Risk Factors
Contributing to Mortality in Patients with Staphylococcus aureus Bacteremia and
Infective Endocarditis.

2013-2014

Daniel Pepe (BSc, MD Candidate): Predictors of Mortality in Patients with
Staphylococcus aureus Bacteremia.

2012-2014

James Choi (MD): Comparison of COVATS and Conventional Thoracotomy for
Resection of Lung Cancer at the London Health Sciences Centre.

2012-2014

Scott Rieder (MD): Evaluation of Wait-times for Surgical Resection of
Colorectal Cancer Following Diagnostic Colonoscopy at the London Health
Sciences Centre.

GRANT SUPPORT
Current Funding Support:
Academic Medical Organization of Southwestern Ontario (AMOSO) Innovation Fund (INN14-006), May
1, 2014 – April 30, 2016. Evidence-based medicine for the enhanced management of complicated
Staphylococcus aureus infections: Can we do better? Co-investigator, $97 400.
Pending Funding Support:
Department of Surgery (Western University, London, Ontario) Internal Research Fund, July 1, 2014 to
June 30, 2016. Analysis of immune determinants involved in liver hypertrophy following Associated
Liver Partition Prior to Staged Hepatectomy (ALPPS). Co-investigator, $20 000 (pending).
PATENTS AND PATENT APPLICATIONS
1.

Anantha RV, McCormick JK, Haeryfar SMM. 2014. “Modulation of invariant Natural Killer T
Cells in the Treatment of Sepsis” U.S. Provisional Patent No. 61/978,467

ACADEMIC ACTIVITIES
Teaching:
2013
2012-2014
2010-present

Instructor, Clinical Skills Methods for Clinical Clerks, Schulich School of Medicine and
Dentistry, Western University
Instructor, Advanced Trauma Life Support Course, Western University
Resident Teacher for Clinical Clerks, Division of General Surgery, Western University
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Invited Lectures:
2013

“Why is Immunology Important in Medicine?” Invited talk for first-year medical
students, Schulich School of Medicine and Dentistry, Western University

Committees:
2013
2012-2013
2008-2009
2008

Attendee, Western Research Symposium, Western University
Resident Member, Resident Training Committee (General Surgery), Western University
Class Representative, Clerkship Committee, Faculty of Medicine, University of Ottawa
Secretary, ORBIS Vision 2020 East Africa Conference, Dar Es Salaam, Tanzania

Leadership:
2010-present
2013
2008
2007-2008
2007-2008
2011

Attendee, General Surgery Journal Club, Western University, London, Ontario
Resident Judge, Medical Student Poster Sessions, American College of Surgeons
Clinical Congress, Washington D.C.
Participant, Canadian Medical Association Leadership Training Workshop, Ottawa
Organizer, Mentorship Group, Faculty of Medicine, University of Ottawa, Ottawa
Coordinator, Seminars on Manuscripts Revolutionizing Therapies, Faculty of Medicine
Instructor Candidate, Advanced Trauma Life Support Course, University of Western
Ontario, London, Ontario

COMMUNITY ACTIVITIES
2007
2003-2008
2002-2005

Performer, Faculty of Medicine MedShow, University of Ottawa
Guitar performer, Ottawa
English and Math tutor, Kumon Education Centre, Ottawa
Volunteered as a tutor in English and Math for underprivileged children in a south
Ottawa neighborhood
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